Form 10-Q
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

COMMISSION FILE NUMBER 001-16789

 

 

 

LOGO

ALERE INC.

(Exact name of registrant as specified in its charter)

 

 

 

DELAWARE   04-3565120

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

51 SAWYER ROAD, SUITE 200

WALTHAM, MASSACHUSETTS 02453

(Address of principal executive offices) (Zip code)

(781) 647-3900

(Registrant’s telephone number, including area code)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   x    Accelerated filer   ¨
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

The number of shares outstanding of the registrant’s common stock, par value of $0.001 per share, as of August 30, 2016 was 86,740,318.

 

 

 


Table of Contents

ALERE INC.

REPORT ON FORM 10-Q

For the Quarterly Period Ended June 30, 2016

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words. A number of important factors could cause actual results of Alere Inc. and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risk factors detailed in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and other risk factors identified herein or from time to time in our periodic filings with the Securities and Exchange Commission. Readers should carefully review these forward-looking statements and these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to Alere Inc. and its subsidiaries.

TABLE OF CONTENTS

 

         PAGE  

PART I. FINANCIAL INFORMATION

     3   

Item 1.

 

Financial Statements (unaudited)

     3   
 

a) Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2016 and 2015

     3   
 

b) Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2016 and 2015

     4   
 

c) Consolidated Balance Sheets as of June 30, 2016 and December  31, 2015

     5   
 

d) Consolidated Statements of Cash Flows for the Six Months Ended June  30, 2016 and 2015

     6   
 

e) Notes to Consolidated Financial Statements

     7   

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

     41   

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

     55   

Item 4.

 

Controls and Procedures

     55   

PART II. OTHER INFORMATION

     57   

Item 1.

  Legal Proceedings      57   

Item 1A.

 

Risk Factors

     59   

Item 3.

  Default Upon Senior Securities      59   

Item 6.

  Exhibits      59   

SIGNATURE

     61   

 

2


Table of Contents

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2016     2015     2016     2015  

Net product sales

   $ 483,746      $ 491,049      $ 943,517      $ 975,387   

Services revenue

     124,809        126,628        240,518        250,484   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

     608,555        617,677        1,184,035        1,225,871   

License and royalty revenue

     2,533        5,694        5,262        10,392   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     611,088        623,371        1,189,297        1,236,263   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

     250,398        257,893        487,859        497,994   

Cost of services revenue

     78,294        76,800        151,394        152,426   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

     328,692        334,693        639,253        650,420   

Cost of license and royalty revenue

     535        1,344        1,926        3,294   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

     329,227        336,037        641,179        653,714   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     281,861        287,334        548,118        582,549   

Operating expenses:

        

Research and development

     28,446        27,198        55,508        55,214   

Sales and marketing

     102,516        108,024        202,329        217,103   

General and administrative

     128,354        61,173        243,310        153,864   

Impairment and (gain) loss on dispositions, net

     —          5,542        (3,810     40,334   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     22,545        85,397        50,781        116,034   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (42,329     (59,494     (84,435     (105,925

Other income (expense), net

     (14,112     3,195        (15,461     828   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before provision for income taxes

     (33,896     29,098        (49,115     10,937   

Provision (benefit) for income taxes

     3,117        15,689        2,909        7,836   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax

     (37,013     13,409        (52,024     3,101   

Equity earnings of unconsolidated entities, net of tax

     2,122        1,361        7,156        5,320   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations

     (34,891     14,770        (44,868     8,421   

Income from discontinued operations, net of tax

     —         —         —          216,777   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

     (34,891     14,770        (44,868     225,198   

Less: Net income attributable to non-controlling interests

     143        359        246        447   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to Alere Inc. and Subsidiaries

     (35,034     14,411        (45,114     224,751   

Preferred stock dividends

     (5,308     (5,308     (10,617     (10,558
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) available to common stockholders

   $ (40,342   $ 9,103      $ (55,731   $ 214,193   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic net income (loss) per common share:

        

Income (loss) from continuing operations

   $ (0.46   $ 0.11      $ (0.64   $ (0.03

Income from discontinued operations

     —         —         —          2.56   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) per common share

   $ (0.46   $ 0.11      $ (0.64   $ 2.53   
  

 

 

   

 

 

   

 

 

   

 

 

 

Diluted net income (loss) per common share:

        

Income (loss) from continuing operations

   $ (0.46   $ 0.11      $ (0.64   $ (0.03

Income from discontinued operations

     —         —         —          2.56   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) per common share

   $ (0.46   $ 0.11      $ (0.64   $ 2.53   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares — basic

     86,737        85,173        86,692        84,758   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average shares — diluted

     86,737        86,635        86,692        84,758   
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

3


Table of Contents

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(unaudited)

(in thousands)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2016     2015     2016     2015  

Net income (loss)

   $ (34,891   $ 14,770      $ (44,868   $ 225,198   
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax:

        

Changes in cumulative translation adjustment

     (44,135     46,726        (21,942     (33,616

Minimum pension liability adjustment

     531        (374     686        (1,756
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax

     (43,604     46,352        (21,256     (35,372
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     (43,604     46,352        (21,256     (35,372
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (78,495     61,122        (66,124     189,826   

Less: Comprehensive income attributable to non-controlling interests

     143        359        246        447   
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries

   $ (78,638   $ 60,763      $ (66,370   $ 189,379   
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

4


Table of Contents

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands, except par value)

 

     June 30, 2016     December 31, 2015  
ASSETS     

Current assets:

    

Cash and cash equivalents

   $ 506,164      $ 502,200   

Restricted cash

     5,662        5,694   

Marketable securities

     74        164   

Accounts receivable, net of allowances of $92,983 and $89,701 at June 30, 2016 and December 31, 2015, respectively

     427,222        445,833   

Inventories, net

     333,846        347,001   

Prepaid expenses and other current assets

     162,339        152,233   

Assets held for sale – current

     —          4,165   
  

 

 

   

 

 

 

Total current assets

     1,435,307        1,457,290   

Property, plant and equipment, net

     438,787        446,039   

Goodwill

     2,811,545        2,836,915   

Other intangible assets with indefinite lives

     28,279        28,110   

Finite-lived intangible assets, net

     909,208        997,281   

Restricted cash

     42,589        43,228   

Other non-current assets

     16,290        18,078   

Investments in unconsolidated entities

     74,511        65,333   

Deferred tax assets

     18,638        13,993   

Non-current income tax receivable

     3,517        3,517   

Assets held for sale – non-current

     12,223        13,337   
  

 

 

   

 

 

 

Total assets

   $ 5,790,894      $ 5,923,121   
  

 

 

   

 

 

 
LIABILITIES AND EQUITY     

Current liabilities:

    

Short-term debt and current portion of long-term debt

   $ 43,681      $ 199,992   

Current portion of capital lease obligations

     3,500        3,962   

Accounts payable

     194,235        195,752   

Accrued expenses and other current liabilities

     320,526        324,465   

Liabilities related to assets held for sale – current

     —          363   
  

 

 

   

 

 

 

Total current liabilities

     561,942        724,534   
  

 

 

   

 

 

 

Long-term liabilities:

    

Long-term debt, net of current portion

     2,920,789        2,831,166   

Capital lease obligations, net of current portion

     6,972        7,181   

Deferred tax liabilities

     140,864        147,618   

Other long-term liabilities

     148,165        154,193   
  

 

 

   

 

 

 

Total long-term liabilities

     3,216,790        3,140,158   
  

 

 

   

 

 

 

Commitments and contingencies

    

Stockholders’ equity:

    

Series B preferred stock, $0.001 par value (liquidation preference: $709,701 at June 30, 2016 and $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at June 30, 2016 and December 31, 2015; Outstanding: 1,774 shares at June 30, 2016 and December 31, 2015

     606,406        606,468   

Common stock, $0.001 par value; Authorized: 200,000 shares; Issued: 94,419 shares at June 30, 2016 and 94,043 shares at December 31, 2015; Outstanding: 86,740 shares at June 30, 2016 and 86,364 shares at December 31, 2015

     94        94   

Additional paid-in capital

     3,458,639        3,438,732   

Accumulated deficit

     (1,511,481     (1,466,381

Treasury stock, at cost, 7,679 shares at June 30, 2016 and December 31, 2015

     (184,971     (184,971

Accumulated other comprehensive loss

     (361,033     (339,777
  

 

 

   

 

 

 

Total stockholders’ equity

     2,007,654        2,054,165   

Non-controlling interests

     4,508        4,264   
  

 

 

   

 

 

 

Total equity

     2,012,162        2,058,429   
  

 

 

   

 

 

 

Total liabilities and equity

   $ 5,790,894      $ 5,923,121   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

5


Table of Contents

ALERE INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

 

     Six Months Ended June 30,  
     2016     2015  

Cash Flows from Operating Activities:

    

Net income (loss)

   $ (44,868   $ 225,198   

Income from discontinued operations, net of tax

     —          216,777   
  

 

 

   

 

 

 

Income (loss) from continuing operations

     (44,868     8,421   

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

    

Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

     5,261        7,784   

Depreciation and amortization

     142,405        147,103   

Non-cash stock-based compensation expense

     20,607        12,279   

Impairment of inventory

     870        68   

Impairment of long-lived assets

     633        387   

Loss on disposition of fixed assets

     4,235        3,318   

Equity earnings of unconsolidated entities, net of tax

     (7,156     (5,320

Gain on sales of marketable securities

     —          (8

Deferred income taxes

     (13,210     (42,171

(Gain) loss related to impairment and net loss on dispositions

     (3,810     40,334   

(Gain) loss on extinguishment of debt

     —          3,480   

Other non-cash items

     9,720        (2,332

Non-cash change in fair value of contingent purchase price consideration

     (1,780     (52,867

Changes in assets and liabilities, net of acquisitions:

    

Accounts receivable, net

     20,023        (18,016

Inventories, net

     (5,820     (45,219

Prepaid expenses and other current assets

     (24,881     (27,077

Accounts payable

     (1     (23,251

Accrued expenses and other current liabilities

     (1,676     23,052   

Other non-current liabilities

     (6,106     8,536   

Cash paid for contingent purchase price consideration

     (324     (3,781
  

 

 

   

 

 

 

Net cash provided by continuing operations

     94,122        34,720   

Net cash provided by discontinued operations

     —          318   
  

 

 

   

 

 

 

Net cash provided by operating activities

     94,122        35,038   
  

 

 

   

 

 

 

Cash Flows from Investing Activities:

    

Increase in restricted cash

     (449     (424,025

Purchases of property, plant and equipment

     (32,318     (47,284

Proceeds from sale of property, plant and equipment

     892        1,120   

Cash received from dispositions, net of cash divested

     21,470        586,625   

Cash paid for business acquisitions, net of cash acquired

     (5,958 )     —    

Cash received from equity method investments

     2,383        14,297   

Cash received from sales of marketable securities

     90        93   

Cash paid for investments

     (184 )     —    

Decrease in other assets

     495        1,750   
  

 

 

   

 

 

 

Net cash provided by (used in) continuing operations

     (13,579     132,576   

Net cash used in discontinued operations

     —          (209
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     (13,579     132,367   
  

 

 

   

 

 

 

Cash Flows from Financing Activities:

    

Cash paid for financing costs

     (19,564     (15,731

Cash paid for contingent purchase price consideration

     (485     (6,373

Proceeds from issuance of common stock, net of issuance costs

     11,124        56,332   

Proceeds from issuance of long-term debt

     381        2,121,851   

Payments on short-term debt

     (791     (584

Payments on long-term debt

     (177,637     (2,118,264

Net (payments) proceeds under revolving credit facilities

     126,213        (126,320

Cash paid for dividends

     (10,646     (10,646

Principal payments on capital lease obligations

     (2,210     (2,910
  

 

 

   

 

 

 

Net cash used in continuing operations

     (73,615     (102,645

Net cash used in discontinued operations

     —          (76
  

 

 

   

 

 

 

Net cash used in financing activities

     (73,615     (102,721
  

 

 

   

 

 

 

Foreign exchange effect on cash and cash equivalents

     (2,964     (1,574
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

     3,964        63,110   

Cash and cash equivalents, beginning of period – continuing operations

     502,200        378,461   

Cash and cash equivalents, beginning of period – discontinued operations

     —          23,300   
  

 

 

   

 

 

 

Cash and cash equivalents, end of period

     506,164        464,871   

Less: Cash and cash equivalents of discontinued operations, end of period

     —         —    
  

 

 

   

 

 

 

Cash and cash equivalents of continuing operations, end of period

   $ 506,164      $ 464,871   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

6


Table of Contents

ALERE INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(1) Basis of Presentation of Financial Information

The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015.

Certain amounts presented may not recalculate directly, due to rounding.

(2) Revision of Previously Reported Consolidated Financial Statements

In connection with the preparation of our consolidated financial statements for the fiscal year ended December 31, 2015, we determined that, in fiscal years 2013 and 2014, each of the interim periods of 2014 and the first three quarters of fiscal year 2015, we had incorrectly reported the timing of recognition of certain revenue transactions for such periods. As a result, we revised our consolidated financial statements as of December 31, 2014 and for the fiscal years ended December 31, 2014 and 2013, each of the interim periods in 2014 and the first three quarters of fiscal year 2015.

Specifically, the errors in the application of U.S. GAAP rules regarding the timing of revenue recognition primarily related to: (i) transactions, principally in Africa, in which we recognized revenue when the product shipped to the distributor, but we contractually retained title in the products until the distributor paid for the products in full or the distributor was not obligated to pay us until the products were sold through to the end-user; (ii) “bill and hold” transactions, principally in China, which did not meet the criteria for revenue recognition under U.S. GAAP; and (iii) other transactions, in which we recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer.

These errors required adjustments to the period in which certain revenues were recognized so that such revenues were recognized in the period in which: physical delivery occurred as defined by the contractual relationship; title and risk of loss had transferred to the buyer; or the buyer had the contractual obligation to pay the amounts invoiced, as required by U.S. GAAP revenue recognition rules and our accounting policy relating to revenue recognition. The impact of these adjustments was a decrease in revenue of $5.8 million and $1.0 million for the three and six months ended June 30, 2015, respectively.

Additionally, we have reflected other out-of-period adjustments in the periods in which such adjustments originated. These adjustments were identified during the financial closing process in connection with the fiscal years ended December 31, 2014 and 2013 and the first three quarters of fiscal year 2015 but were not reflected in our prior filings because they were deemed immaterial. The financial statements included in this Quarterly Report on Form 10-Q have been adjusted to include the adjustments in the period in which these items originated. These out-of-period adjustments are treated as corrections to our prior period financial results. For the three months ended June 30, 2015 these adjustments include a $1.2 million increase in operating expenses related to a bonus accrual, a $1.1 million increase in other income and expense, net due to the measurement of a royalty obligation and the income tax impact of these adjustments. For the six months ended June 30, 2015 these adjustments include a $1.2 million increase in operating expenses related to a bonus accrual, a $2.2 million increase in other income and expense, net due to the measurement of a royalty obligation and the income tax impact of these adjustments. Although management has determined that the errors, as well as the revenue recognition issues noted in the preceding paragraphs, individually and in the aggregate, were not material to prior periods, the financial statements for the three and six months ended June 30, 2015, included herein, have been revised to correct for the impact of these items. Unless otherwise indicated, the consolidated financial information as of and for the three and six months ended June 30, 2015 presented in this Quarterly Report on Form 10-Q reflects these revisions.

 

7


Table of Contents

The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts:

 

     Three Months Ended June 30, 2015  
Revised Consolidated Statement of Operations (in thousands, except per share
data)
   As Previously Reported      Adjustment      As Revised  

Net product sales

   $ 496,834       $ (5,785    $ 491,049   

Net product sales and services revenue

   $ 623,462       $ (5,785    $ 617,677   

Net revenue

   $ 629,156       $ (5,785    $ 623,371   

Cost of net product sales

   $ 258,485       $ (592    $ 257,893   

Cost of service revenue

   $ 76,753       $ 47       $ 76,800   

Cost of net product sales and services revenue

   $ 335,238       $ (545    $ 334,693   

Cost of net revenue

   $ 336,582       $ (545    $ 336,037   

Gross profit

   $ 292,574       $ (5,240    $ 287,334   

Sales and marketing

   $ 107,184       $ 840       $ 108,024   

General and administrative

   $ 60,813       $ 360       $ 61,173   

Operating income

   $ 91,837       $ (6,440    $ 85,397   

Other income (loss), net

   $ 4,260       $ (1,065    $ 3,195   

Income from continuing operations before provision for income taxes

   $ 36,603       $ (7,505    $ 29,098   

Provision for income taxes

   $ 17,701       $ (2,012    $ 15,689   

Income from continuing operations before equity earnings of unconsolidated entities, net of tax

   $ 18,902       $ (5,493    $ 13,409   

Income from continuing operations

   $ 20,263       $ (5,493    $ 14,770   

Net income

   $ 20,263       $ (5,493    $ 14,770   

Net income attributable to Alere Inc. and Subsidiaries

   $ 19,904       $ (5,493    $ 14,411   

Net income available to common stockholders

   $ 14,596       $ (5,493    $ 9,103   

Basic and diluted income per common share: Income from continuing operations

   $ 0.17       $ (0.06 )    $ 0.11   

Basic and diluted net income per common share: Net income per common share

   $ 0.17       $ (0.06    $ 0.11   
     Six Months Ended June 30, 2015  
Revised Consolidated Statement of Operations (in thousands, except per share
data)
   As Previously Reported      Adjustment      As Revised  

Net product sales

   $ 976,433       $ (1,046    $ 975,387   

Net product sales and services revenue

   $ 1,226,917       $ (1,046    $ 1,225,871   

Net revenue

   $ 1,237,309       $ (1,046    $ 1,236,263   

Cost of net product sales

   $ 497,122       $ 872       $ 497,994   

Cost of service revenue

   $ 152,334       $ 92       $ 152,426   

Cost of net product sales and services revenue

   $ 649,456       $ 964       $ 650,420   

Cost of net revenue

   $ 652,750       $ 964       $ 653,714   

Gross profit

   $ 584,559       $ (2,010    $ 582,549   

Sales and marketing

   $ 216,263       $ 840       $ 217,103   

General and administrative

   $ 153,504       $ 360       $ 153,864   

Operating income

   $ 119,244       $ (3,210    $ 116,034   

Other income (loss), net

   $ 2,990       $ (2,162    $ 828   

Income from continuing operations before benefit for income taxes

   $ 16,309       $ (5,372    $ 10,937   

Provision for income taxes

   $ 8,915       $ (1,079    $ 7,836   

Income from continuing operations before equity earnings of unconsolidated entities, net of tax

   $ 7,394       $ (4,293    $ 3,101   

Income from continuing operations

   $ 12,714       $ (4,293    $ 8,421   

Net income

   $ 229,491       $ (4,293    $ 225,198   

Net income attributable to Alere Inc. and Subsidiaries

   $ 229,044       $ (4,293    $ 224,751   

Net income available to common stockholders

   $ 218,486       $ (4,293    $ 214,193   

Basic and diluted income (loss) per common share: Income (loss) from continuing operations

   $ 0.02       $ (0.05    $ (0.03

Basic and diluted net income per common share: Net income per common share

   $ 2.54       $ (0.01    $ 2.53   

 

8


Table of Contents
     Three Months Ended June 30, 2015  
Revised Consolidated Statement of Comprehensive Loss (in thousands)    As Previously Reported      Adjustment      As Revised  

Net income

   $ 20,263       $ (5,493    $ 14,770   

Comprehensive income

   $      66,615       $ (5,493    $      61,122   

Comprehensive income attributable to Alere Inc. and Subsidiaries

   $ 66,256       $ (5,493    $ 60,763   
     Six Months Ended June 30, 2015  
Revised Consolidated Statement of Comprehensive Loss (in thousands)    As Previously Reported      Adjustment      As Revised  

Net income

   $ 229,491       $ (4,293    $ 225,198   

Comprehensive income

   $ 194,119       $ (4,293    $ 189,826   

Comprehensive income attributable to Alere Inc. and Subsidiaries

   $ 193,672       $ (4,293    $ 189,379   
     Six Months Ended June 30, 2015  
Revised Consolidated Statement of Cash Flows (in thousands)    As Previously Reported      Adjustment      As Revised  

Net income

   $ 229,491       $ (4,293    $ 225,198   

Income from continuing operations

   $ 12,714       $ (4,293    $ 8,421   

Depreciation and amortization

   $ 147,011       $ 92       $ 147,103   

Deferred income taxes

   $ (40,655    $ (1,516    $ (42,171

Accounts receivable, net

   $ (27,464    $ 9,448       $ (18,016

Inventories, net

   $ (46,093    $ 874       $ (45,219

Accrued expenses and other current liabilities

   $ 27,657       $ (4,605    $ 23,052   

Other non-current liabilities

   $ 6,025       $ 2,511       $ 8,536   

Net cash provided by continuing operations

   $ 32,209       $ 2,511       $ 34,720   

Net cash provided by operating activities

   $ 32,527       $ 2,511       $ 35,038   

Excess tax benefits on exercised stock options

   $ 2,511       $ (2,511    $ —     

Net cash used in continuing operations

   $ (100,134    $ (2,511    $ (102,645

Net cash used in financing activities

   $ (100,210    $ (2,511    $ (102,721

We have also reflected these corrections as applicable in our consolidated financial statements and our consolidating financial statements presented in Note 22 Guarantor Financial Information.

(3) Merger Agreement

Merger Agreement with Abbott Laboratories

On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a newly formed, wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, holders of shares of our common stock will receive $56.00 in cash, without interest, in exchange for each share of common stock. Each share of our Series B Convertible Perpetual Preferred Stock, par value $0.001 per share, or Series B Preferred Stock, issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. The Merger Agreement was approved by our board of directors. Completion of the merger is subject to customary closing conditions, including (1) the adoption of the Merger Agreement by the affirmative vote of the holders of at least a majority of all outstanding shares of our common stock, (2) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger and (3) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Merger Agreement. The Merger Agreement contains certain termination rights and provides that, upon termination of the Merger Agreement under certain circumstances, Alere would be required to pay Abbott a termination fee equal to $177.0 million.

On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act to not less than 60 days after Abbott and Alere have certified substantial compliance with the second request, unless the period is further extended voluntarily by the

 

9


Table of Contents

parties or terminated sooner by the FTC. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. Under the terms of the Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Merger Agreement, subject to certain exceptions set forth in the Merger Agreement.

On August 25, 2016, we filed a complaint against Abbott in Delaware Chancery Court, which seeks to compel Abbott to fulfill its obligations under the terms of the Merger Agreement to take all actions necessary to promptly obtain all required antitrust approvals for the merger. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We have asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement.

(4) Discontinued Operations

On January 9, 2015, we completed the sale of our health management business to OptumHealth Care Solutions for a purchase price of $599.9 million. We used the net cash proceeds of the sale to repay $575.0 million in aggregate principal amount of outstanding indebtedness under our prior credit facility.

The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statements of operations for the three and six months ended June 30, 2015. The results are as follows (in thousands):

 

     Three and Six Months
Ended June 30, 2015
 

Net revenue

   $ 7,373   

Cost of net revenue

     (4,413

Sales and marketing

     (996

General and administrative

     (5,001

Interest expense

     (9

Other income (expense), net

     160   

Gain on disposal

     366,191   
  

 

 

 

Income from discontinued operations before provision for income taxes

     363,305   

Provision for income taxes

     146,528   
  

 

 

 

Income from discontinued operations, net of tax

   $ 216,777   
  

 

 

 

(5) Cash and Cash Equivalents

We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At June 30, 2016, our cash equivalents consisted of money market funds.

(6) Inventories

Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands):

 

     June 30, 2016      December 31, 2015  

Raw materials

   $ 121,904       $ 130,171   

Work-in-process

     74,206         69,178   

Finished goods

     137,736         147,652   
  

 

 

    

 

 

 
   $ 333,846       $ 347,001   
  

 

 

    

 

 

 

 

10


Table of Contents

(7) Stock-based Compensation

We recorded stock-based compensation expense in our consolidated statements of operations for the three and six months ended June 30, 2016 and 2015, respectively, as follows (in thousands):

 

     Three Months Ended June 30,      Six Months Ended June 30,  
     2016      2015      2016      2015  

Cost of net revenue

   $ 601       $ 287       $ 1,080       $ 540   

Research and development

     481         282         879         606   

Sales and marketing

     2,636         1,251         4,561         2,345   

General and administrative

     7,286         5,310         14,086         8,788   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 11,004       $ 7,130       $ 20,607       $ 12,279   
  

 

 

    

 

 

    

 

 

    

 

 

 

(8) Net Income (Loss) per Common Share

The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share amounts):

 

     Three Months Ended June 30,      Six Months Ended June 30,  
     2016      2015      2016      2015  

Basic and diluted net income (loss) per common share:

           

Numerator:

           

Income (loss) from continuing operations

   $ (34,891    $ 14,770       $ (44,868    $ 8,421   

Preferred stock dividends

     (5,308      (5,308      (10,617      (10,558
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) from continuing operations attributable to common shares

     (40,199      9,462         (55,485      (2,137

Less: Net income attributable to non-controlling interest

     143         359         246         447   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries

     (40,342      9,103         (55,731      (2,584

Income from discontinued operations

     —          —           —           216,777   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income (loss) available to common stockholders

   $ (40,342    $ 9,103       $ (55,731    $ 214,193   
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted-average common shares outstanding — basic

     86,737         85,173         86,692         84,758   
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted-average common shares outstanding — diluted

     86,737         86,635         86,692         84,758   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic net income (loss) per common share:

           

Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries

   $ (0.46    $ 0.11       $ (0.64    $ (0.03

Income from discontinued operations

     —          —           —           2.56   
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic net income (loss) per common share

   $ (0.46    $ 0.11       $ (0.64    $ 2.53   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted net income (loss) per common share:

           

Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries

   $ (0.46    $ 0.11       $ (0.64    $ (0.03

Income from discontinued operations

     —          —           —           2.56   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted net income (loss) per common share

   $ (0.46    $ 0.11       $ (0.64    $ 2.53   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

11


Table of Contents

The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share because the inclusion thereof would be antidilutive (in thousands):

 

     Three Months Ended June 30,      Six Months Ended June 30,  
     2016      2015      2016      2015  

Denominator:

           

Options to purchase shares of common stock

     7,329         7,627         7,329         7,627   

Warrants

     —          —           —           4   

Conversion shares related to 3% convertible senior subordinated notes

     1,687         3,411         2,549         3,411   

Conversion shares related to subordinated convertible promissory notes

     —           27         —           27   

Conversion shares related to Series B convertible preferred stock

     10,238         10,239         10,238         10,239   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding

     19,254         21,304         20,116         21,308   
  

 

 

    

 

 

    

 

 

    

 

 

 

(9) Stockholders’ Equity and Non-controlling Interests

(a) Preferred Stock

For the three and six months ended June 30, 2016, Series B preferred stock dividends amounted to $5.3 million and $10.6 million, respectively, and for the three and six months ended June 30, 2015, Series B preferred stock dividends amounted to $5.3 million and $10.6 million, respectively, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the respective periods. As of June 30, 2016, $5.3 million of Series B preferred stock dividends was accrued. As of July 15, 2016, payments have been made covering all dividend periods through June 30, 2016.

The Series B preferred stock dividends for the three and six months ended June 30, 2016 and 2015 were paid in cash in the subsequent quarters.

(b) Changes in Stockholders’ Equity and Non-controlling Interests

A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the six months ended June 30, 2016 is provided below (in thousands):

 

     Six Months Ended June 30, 2016  
     Total
Stockholders’
Equity
     Non-
controlling
Interests
     Total
Equity
 

Equity, beginning of period

   $ 2,054,165       $ 4,264       $ 2,058,429   

Issuance of common stock under employee compensation plans

     11,308         —          11,308   

Net issuance of common stock to settle taxes on restricted stock units

     (1,410      —          (1,410

Preferred stock dividends

     (10,646      —          (10,646

Stock-based compensation expense

     20,607         —          20,607   

Other adjustments

     —          (2      (2

Net income (loss)

     (45,114      246         (44,868

Total other comprehensive loss

     (21,256      —          (21,256
  

 

 

    

 

 

    

 

 

 

Equity, end of period

   $ 2,007,654       $ 4,508       $ 2,012,162   
  

 

 

    

 

 

    

 

 

 

(10) Business Combinations

Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner.

 

12


Table of Contents

Net assets acquired are recorded at their estimated fair value and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized.

Acquisition in 2016

EDTS

On February 11, 2016, we acquired the shares of European Drug Testing Services EDTS AB, or EDTS, located in Lidingo, Sweden, a provider of services related to on-site drug testing. The aggregate purchase price was approximately $6.5 million and was paid in cash. The operating results of EDTS are included in our professional diagnostics reporting unit and business segment.

Our consolidated statements of operations for the three and six months ended June 30, 2016 included revenue totaling approximately $1.7 million and $2.6 million, respectively, related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $2.1 million, which is deductible for tax purposes.

A summary of the preliminary fair values of the net assets acquired from EDTS is as follows (in thousands):

 

     Fair Value  

Current assets

   $ 1,371   

Property, plant and equipment

     115   

Goodwill

     2,065   

Intangible assets

     4,220   
  

 

 

 

Total assets acquired

   $ 7,771   
  

 

 

 

Current liabilities

   $ 1,301   
  

 

 

 

Total liabilities assumed

   $ 1,301   
  

 

 

 

Net assets acquired

   $ 6,470   
  

 

 

 

Cash paid

   $ 6,470   
  

 

 

 

The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective preliminary fair values and weighted-average useful lives (dollars in thousands):

 

     Fair Value      Weighted-
average
Useful Life
 

Core technology and patents

   $ 540         10.0 years   

Trademarks and trade names

     310         20.0 years   

Customer relationships

     2,800         14.0 years   

Non-compete agreements

     570         3.0 years   
  

 

 

    

Total intangible assets

   $ 4,220      
  

 

 

    

 

13


Table of Contents

(11) Restructuring

The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and six months ended June 30, 2016 and 2015 (in thousands):

 

     Three Months Ended June 30,      Six Months Ended June 30,  

Statement of Operations Caption

   2016      2015      2016      2015  

Cost of net revenue

   $ 1,103       $ 896       $ 2,370       $ 2,399   

Research and development

     1,034         156         2,954         649   

Sales and marketing

     259         570         909         1,953   

General and administrative

     6,389         3,231         10,215         4,122   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total operating expenses

     8,785         4,853         16,448         9,123   

Interest expense, including amortization of original issue discounts and deferred financing costs

     2         6         7         13   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total restructuring charges

   $ 8,787       $ 4,859       $ 16,455       $ 9,136   
  

 

 

    

 

 

    

 

 

    

 

 

 

(a) Restructuring Plans

During 2016, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our manufacturing and supply chain, and research and development groups, as well as closing certain business locations in Europe and the United States. The following table summarizes the restructuring activities related to the 2016 restructuring plans, in addition to our earlier restructuring plans as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three and six months ended June 30, 2016 and 2015 and since inception of these restructuring plans (in thousands):

 

     Three Months Ended
June 30,
    Six Months Ended
June 30,
    Since
Inception
 

Professional Diagnostics

   2016     2015     2016     2015        

Severance-related costs

   $ 3,183      $ 1,264      $ 6,274      $ 4,064      $ 44,261   

Facility and transition costs

     213        2,581        1,194        4,007        12,862   

Other exit costs

     2        6        7        13        829   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash charges

     3,398        3,851        7,475        8,084        57,952   

Fixed asset and inventory impairments

     21        445        419        454        16,372   

Other non-cash charges

     (3     —          210        —          2,192   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total professional diagnostics charges

   $ 3,416      $ 4,296      $ 8,104      $ 8,538      $ 76,516   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Corporate and Other

                              

Severance-related costs

   $ (19   $ 569      $ (4   $ 611      $ 4,273   

Facility and transition costs

     5,390        (6     8,355        (13     19,677   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total corporate and other charges

   $ 5,371      $ 563      $ 8,351      $ 598      $ 23,950   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total restructuring charges

   $ 8,787      $ 4,859      $ 16,455      $ 9,136      $ 100,466   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

We anticipate incurring approximately $4.4 million and $8.0 million in additional costs under our 2016 restructuring plans related to our professional diagnostics and corporate and other business segments, respectively, primarily related to integration and operational initiatives and site closures. We may develop additional restructuring plans over the remainder of 2016. In addition, we anticipate incurring approximately $3.7 million in additional costs under earlier restructuring plans as in effect at June 30, 2016, primarily related to the closure of our manufacturing facility in Israel.

(b) Restructuring Reserves

The following table summarizes our restructuring reserves related to the plans described above, of which $9.5 million is included in accrued expenses and other current liabilities and $0.6 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands):

 

     Severance-
related
Costs
     Facility and
Transition
Costs
     Other Exit
Costs
     Total  

Balance, December 31, 2015

   $ 1,633       $ 1,966       $ 180       $ 3,779   

Cash charges

     6,270         9,549         7         15,826   

Payments

     (3,814      (5,645      (73      (9,532

Currency adjustments

     (18      11         —          (7
  

 

 

    

 

 

    

 

 

    

 

 

 

Balance, June 30, 2016

   $ 4,071       $ 5,881       $ 114       $ 10,066   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

14


Table of Contents

(12) Long-term Debt

We had the following long-term debt balances outstanding (in thousands):

 

     June 30, 2016      December 31, 2015  

A term loans(1)(2)

   $ 559,317       $ 575,746   

B term loans(1)(2)

     958,337         965,740   

Revolving loans(1)

     125,000         —     

7.25% Senior notes(2)

     442,533         446,320   

6.5% Senior subordinated notes(2)

     415,679         419,209   

6.375% Senior subordinated notes(2)

     414,033         418,133   

3% Convertible senior subordinated notes(3)

     —           149,839   

Other lines of credit

     1,335         136   

Other

     48,236         56,035   
  

 

 

    

 

 

 
     2,964,470         3,031,158   

Less: Short-term debt and current portion of long-term debt

     (43,681      (199,992
  

 

 

    

 

 

 

Long-term debt

   $ 2,920,789       $ 2,831,166   
  

 

 

    

 

 

 

 

(1) Incurred under our secured credit facility entered into on June 18, 2015.
(2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. On June 30, 2016, we were not in default under the Credit Agreement or the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file this Quarterly Report on Form 10-Q. At September 1, 2016, we were in default under the indentures governing our outstanding notes with respect to our failure to timely file this Quarterly Report on Form 10-Q and, by filing this Quarterly Report on Form 10-Q prior to the expiration of the applicable cure periods under the notes, we have cured this default.
(3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016.

 

15


Table of Contents

In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs

of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and

six months ended June 30, 2016 and 2015 as follows (in thousands):

 

     Three Months Ended June 30,      Six Months Ended June 30,  
     2016      2015      2016      2015  

Secured credit facility (1)

   $ 17,834       $ 12,851       $ 34,877       $ 12,851   

Prior credit facility (2) (3)

     —           19,726         —           39,188   

7.25% Senior notes

     8,904         8,525         17,428         17,049   

6.5% Senior subordinated notes

     7,405         7,234         14,636         14,467   

6.375% Senior subordinated notes

     7,112         542         14,115         542   

8.625% Senior subordinated notes

     —           9,274         —           18,547   

3% Convertible senior subordinated convertible notes

     603         1,246         1,847         2,492   

Other

     471         96         1,532         789   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 42,329       $ 59,494       $ 84,435       $ 105,925   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) Includes “A” term loans, “B” term loans, and revolving line of credit loans.
(2)  Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. For the three and six months ended June 30, 2015, the amounts include $0.3 million and $0.7 million, respectively, related to the amortization of fees paid for certain debt modifications.
(3)  Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility.

April and August 2016 Amendments to Secured Credit Facility

On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for the year ended December 31, 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of certain financial statements as a result of our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the audit of our financial statements for the year ended December 31, 2015, to the extent that such breach is due to our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for the year ended December 31, 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we were required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016. We made the required deliveries before that date. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.250% of the sum of (i) the aggregate principal amount of such lender’s Term Loans (as defined in the Credit Agreement) outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $4.5 million in the aggregate for all consenting lenders. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. The amendment also increased the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility.

On August 18, 2016, we and the requisite lenders under the Credit Agreement entered into a further amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) (x) the financial statements and certain related deliverables for the three months ended March 31, 2016, which we refer to as the Q1 Financial Reports, by the applicable deadline under the Credit Agreement or (y) the financial statements and certain related deliverables for the three months ended June 30, 2016, which we refer to as the Q2 Financial Reports, by the applicable deadline under the Credit Agreement, and (ii) extend the deadline for delivery of the Q1 Financial Reports to August 25, 2016 and the deadline for the delivery of the Q2 Financial Reports to September 13, 2016. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.125% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment outstanding on the effective date of the amendment, or approximately $2.2 million in the aggregate for all consenting lenders. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt.

 

16


Table of Contents

May 2016 Waivers with respect to Senior Notes and Senior Subordinated Notes

On April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and our subsequent Quarterly Reports on Form 10-Q, or the Failures to File. In connection with the Failures to File, we paid, in May and July 2016, to each holder of Notes who validly delivered a consent aggregate cash payments equal to $15.00 for each $1,000 aggregate principal amount of such holder’s Notes, or an aggregate of $19.2 million. The waivers were deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt.

Maturity of our 3.0% convertible senior subordinated notes

Our 3% convertible senior subordinated notes matured and were repaid in full on May 15, 2016. Based on the price of our common stock on the date of maturity, we paid all outstanding principal and accrued interest owing under such notes in cash. The aggregate amount paid to the noteholders at maturity was approximately $152.0 million, consisting of $125.0 million in cash drawn under our revolving credit facility plus $27.0 million of cash available on such date.

(13) Fair Value Measurements

We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value.

Described below are the three levels of inputs that may be used to measure fair value:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

 

Description

   June 30,
2016
     Quoted Prices in
Active Markets
(Level 1)
     Significant Other
Observable Inputs
(Level 2)
     Unobservable Inputs
(Level 3)
 

Assets:

           

Marketable securities

   $ 74       $ 74       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total assets

   $ 74       $ 74       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Contingent consideration obligations (1)

   $ 55,100       $ —        $ —        $ 55,100   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities

   $       55,100       $ —        $ —        $ 55,100   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

17


Table of Contents

Description

   December 31,
2015
     Quoted Prices in
Active Markets
(Level 1)
     Significant Other
Observable Inputs
(Level 2)
     Unobservable Inputs
(Level 3)
 

Assets:

           

Marketable securities

   $ 164       $ 164       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Total assets

   $ 164       $ 164       $ —        $ —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Contingent consideration obligations (1)

   $ 57,744       $ —        $ —        $ 57,744   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities

   $ 57,744       $ —        $ —        $ 57,744   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) for additional information on the valuation of our contingent consideration obligations.

Changes in the fair value of our Level 3 contingent consideration obligations during the six months ended June 30, 2016 were as follows (in thousands):

 

Fair value of contingent consideration obligations, December 31, 2015

   $ 57,744   

Payments

     (865

Fair value adjustments

     (1,780

Foreign currency adjustments

     1   
  

 

 

 

Fair value of contingent consideration obligations, June 30, 2016

   $ 55,100   
  

 

 

 

At June 30, 2016 and December 31, 2015, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values.

The carrying amount and estimated fair value of our long-term debt (including the current portion) were both $3.0 billion at June 30, 2016. The carrying amount and estimated fair value of our long-term debt (including the current portion) were $3.1 billion and $3.0 billion, respectively, at December 31, 2015. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

(14) Financial Information by Segment

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and members of senior management. We currently have three reportable operating segments: (i) professional diagnostics, (ii) consumer diagnostics and (iii) corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and six months ended June 30, 2016 and 2015 is as follows (in thousands):

 

     Professional
Diagnostics
     Consumer
Diagnostics
     Corporate
and
Other
     Total  

Three Months Ended June 30, 2016:

           

Net revenue

   $ 591,294       $ 19,794       $ —        $ 611,088   

Operating income (loss)

   $ 85,535       $ 396       $ (63,386    $ 22,545   

Depreciation and amortization

   $ 66,393       $ 1,374       $ 2,134       $ 69,901   

Restructuring charge

   $ 3,414       $ —        $ 5,371       $ 8,785   

Stock-based compensation

   $ —        $ —        $ 11,004       $ 11,004   

 

18


Table of Contents
     Professional
Diagnostics
     Consumer
Diagnostics
     Corporate
and
Other
     Total  

Three Months Ended June 30, 2015:

           

Net revenue

   $ 598,726       $ 24,645       $ —        $ 623,371   

Operating income (loss)

   $ 153,241       $ 1,079       $ (68,923    $ 85,397   

Impairment and (gain) loss on dispositions, net

   $ (38,836    $ —        $ 44,378       $ 5,542   

Depreciation and amortization

   $ 70,189       $ 725       $ 1,775       $ 72,689   

Restructuring charge

   $ 4,290       $ —        $ 563       $ 4,853   

Stock-based compensation

   $ —        $ —        $ 7,130       $ 7,130   

Six Months Ended June 30, 2016:

           

Net revenue

   $ 1,152,061       $ 37,236       $ —        $ 1,189,297   

Operating income (loss)

   $ 168,215       $ 563       $ (117,997    $ 50,781   

Impairment and (gain) loss on dispositions, net

   $ (3,810    $ —        $ —        $ (3,810

Depreciation and amortization

   $ 135,225       $ 2,873       $ 4,307       $ 142,405   

Restructuring charge

   $ 8,097       $ —        $ 8,351       $ 16,448   

Stock-based compensation

   $ —        $ —        $ 20,607       $ 20,607   

Six Months Ended June 30, 2015:

           

Net revenue

   $ 1,189,651       $ 46,612       $ —        $ 1,236,263   

Operating income (loss)

   $ 242,784       $ 3,283       $ (130,033    $ 116,034   

Impairment and (gain) loss on dispositions, net

   $ (40,568    $ —        $ 80,902       $ 40,334   

Depreciation and amortization

   $ 142,658       $ 1,436       $ 3,009       $ 147,103   

Restructuring charge

   $ 8,525       $ —        $ 598       $ 9,123   

Stock-based compensation

   $ —        $ —        $ 12,279       $ 12,279   

Assets:

           

As of June 30, 2016

   $ 5,572,046       $ 179,445       $ 39,403       $ 5,790,894   

As of December 31, 2015

   $ 5,619,901       $ 172,551       $ 130,669       $ 5,923,121   

The following tables summarize our net revenue from the professional diagnostics reporting segments by groups of similar products and services for the three and six months ended June 30, 2016 and 2015 (in thousands):

 

     Three Months Ended June 30,      Six Months Ended June 30,  
     2016      2015      2016      2015  

Cardiometabolic

   $ 203,982       $ 211,672       $ 398,559       $ 412,608   

Infectious disease

     190,168         172,834         373,402         358,236   

Toxicology

     158,199         157,495         304,982         306,251   

Other

     36,412         51,031         69,856         102,164   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total professional diagnostics net product sales and services revenue

     588,761         593,032         1,146,799         1,179,259   

License and royalty revenue

     2,533         5,694         5,262         10,392   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total professional diagnostics net revenue

   $ 591,294       $ 598,726       $ 1,152,061       $ 1,189,651   
  

 

 

    

 

 

    

 

 

    

 

 

 

(15) Related Party Transactions

(a) SPD Joint Venture

In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiometabolic, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting.

We had a net payable to SPD of $3.7 million as of June 30, 2016 and $1.2 million as of December 31, 2015. The $3.7 million net payable balance as of June 30, 2016 is net of a receivable of approximately $1.3 million for costs incurred in connection with our 2008 SPD-related restructuring plans. The $1.2 million net payable balance as of December 31, 2015 is net of a receivable of approximately $1.5 million for costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $6.7 million and $8.9 million as of June 30, 2016 and December 31, 2015, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture have been classified as other receivables within prepaid and other current assets on our consolidated balance sheets in the

 

19


Table of Contents

amounts of $8.8 million and $7.8 million as of June 30, 2016 and December 31, 2015, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $21.8 million and $39.5 million during the three and six months ended June 30, 2016, respectively, and $21.7 million and $41.2 million during the three and six months ended June 30, 2015, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.3 million and $0.5 million during the three and six months ended June 31, 2016, respectively, and $0.3 million and $0.6 million during the three and six months ended June 30, 2015, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations.

Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. We defer our profit on products sold to SPD until the products are sold through to the customer. As a result of these related transactions, we have recorded $11.7 million and $9.9 million of trade receivables which are included in accounts receivable on our consolidated balance sheets as of June 30, 2016 and December 31, 2015, respectively, and $31.6 million and $24.9 million of trade accounts payable which are included in accounts payable on our consolidated balance sheets as of June 30, 2016 and December 31, 2015, respectively.

The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands):

 

Balance Sheet Caption

   June 30, 2016      December 31, 2015  

Accounts receivable, net of allowances

   $ 11,670       $ 9,873   

Prepaid expenses and other current assets

   $ 8,768       $ 6,602   

Other non-current assets

   $ 6,699       $ 8,895   

Accounts payable

   $ 31,584       $ 24,887   

As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. During 2015, SPD appealed the district court’s injunction with respect to sales and advertising of such product, which was based on a finding that SPD violated certain laws with respect to the advertising of such product. The appellate court has issued a stay of the injunction, pending the outcome of the appeal. In addition, a class action lawsuit has been initiated against SPD and P&G in the United States District Court for the Central District of California, alleging violations of certain laws in connection with the sales and advertising of one of SPD’s products which claims are based on similar grounds as those at issue in the litigation described above in this paragraph. On August 19, 2016, the class action lawsuit was dismissed with prejudice. The plaintiffs may appeal the decision prior to September 19, 2016. There may be additional lawsuits against SPD or us relating to this matter in the future. The ultimate resolution of these matters is not known at this time, nor is the potential impact they or future litigation may have on SPD or us, including whether any such resolution or any damages imposed by a court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations.

(b) Entrustment Loan Arrangement with SPD Shanghai

Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23 million (approximately $3.5 million at June 30, 2016), in order to finance the latter’s short-term working capital needs, with the Royal Bank of Scotland (China) Co., Ltd. Shanghai Branch, or RBS. The agreement governs the setting up of an Entrustment Loan Account with RBS, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to RBS of amounts borrowed from RBS by SPD Shanghai. The Alere Shanghai RBS account is recorded as restricted cash on our balance sheet and amounted to $3.5 million at June 30, 2016.

(c) TechLab

We have an equity method investment in TechLab, Inc., or TechLab, a company that provides diagnostic testing products used by physicians and other health care customers to diagnose, treat, and monitor intestinal diseases and other medical conditions. We own approximately 49% of Techlab. We have also entered into an exclusive distributor agreement with Techlab. This agreement grants us the global distribution rights to Techlab’s products with certain exceptions. We had trade payables owed to Techlab of $1.5 million and $3.2 million as of June 30, 2016 and December 31, 2015, respectively. We made product purchases from Techlab of $4.5 million and $4.1 million during the three months ended June 30, 2016 and 2015, respectively, and $9.2 million and $8.5 million during the six months ended June 30, 2016 and 2015.

 

20


Table of Contents

(16) Other Arrangements

In September 2014, we entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, to develop diagnostic countermeasures for pandemic influenza. Under the terms of the 3.5 year contract, BARDA has agreed to provide up to $12.9 million to us to support the development of a rapid, molecular, low-cost influenza diagnostic device with PCR-like performance at the point of care. The project is designed to help support future preparedness and medical response to an influenza pandemic. Funding from BARDA is subject to successful completion of various interim feasibility and development milestones as defined in the agreement. For the three months ended June 30, 2016 and 2015, we had incurred $1.0 million and $0.9 million, respectively, of qualified expenditures under the contract, for which we had received cash reimbursement from BARDA in the amount of $0.0 million and $0.5 million, respectively, and $1.0 million and $0.4 million was recorded as a receivable as of June 30, 2016 and 2015, respectively. Reimbursements of qualified expenditures under this contract are recorded as a reduction of our related qualified research and development expenditures.

In February 2013, we entered into an agreement with the Bill & Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of validated, low-cost, nucleic-acid assays and cartridges for clinical tuberculosis detection and drug-resistance testing, and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provided for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. In April 2016, we and the Gates Foundation agreed to mutually terminate this grant and loan agreement and, therefore, there will be no additional grants and no advances will be available under the loan agreement. Prior to its termination, we did not borrow any amounts under the Gates Loan Agreement. As of June 30, 2016, we had received approximately $19.7 million in grant-related funding from the Gates Foundation. Grant funds were recorded upon receipt as restricted cash and deferred grant funding, with the deferred grant funding classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures were incurred under the terms of the grant, we used the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended June 30, 2015, we incurred approximately $1.8 million of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses. There were no amounts remaining as restricted cash or deferred grant funding under the February 2013 grant agreement as of June 30, 2016.

In addition to the February 2013 grant discussed above, we have also been awarded several smaller grants by the Gates Foundation in the aggregate amount of approximately $2.9 million to support the elimination of malaria. We incurred qualifying expenses totaling approximately $0.3 million and $0.1 million for the three months ended June 30, 2016 and 2015, respectively. We incurred qualifying expenses totaling approximately $0.5 million and $0.3 million for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, $1.4 million under these grants was recorded as restricted cash and $1.3 million as deferred grant funding on our accompanying consolidated balance sheet.

(17) Commitments and Contingencies

(a) Acquisition-related Contingent Consideration Obligations

We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our consolidated statements of operations.

Increases or decreases in the fair values of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria.

 

21


Table of Contents

The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions, as follows (in thousands):

 

Acquisition

   Acquisition Date      Acquisition
Date Fair
Value
     Maximum
Remaining
Earn-out
Potential
as of
June 30,
2016
    Remaining
Earn-out
Period as
of
June 30,
2016
    Estimated
Fair Value as
of
June 30,
2016
     Estimated
Fair Value as
of
December 31,
2015
     Payments
Made
During
2016
 

TwistDx, Inc.(1)

     March 11, 2010       $ 35,600       $ 102,870        2016 – 2025 (3)    $ 46,600       $ 47,800       $ 377   

Epocal(2)

     February 1, 2013       $ 75,000       $ 45,500        2016 – 2018        3,900         4,700         —     

Other

     Various       $ 30,373       $ —   (4)      2016        4,600         5,244         488   
            

 

 

    

 

 

    

 

 

 
             $ 55,100       $ 57,744       $ 865   
            

 

 

    

 

 

    

 

 

 

 

(1) The terms of the acquisition agreement require us to pay an earn-out upon successfully meeting certain revenue and product development targets through 2025.
(2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018.
(3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date.
(4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric.

(b) Legal Proceedings

Abbott Laboratories

On August 25, 2016, Alere Inc. filed suit against Abbott Laboratories in the Delaware Chancery Court, and filed an accompanying motion to expedite the proceedings. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We have asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement. On August 30, 2016, Abbott filed its response in opposition to the motion to expedite the proceedings in this matter. On September 2, 2016, the Delaware Chancery Court granted our motion to expedite the proceedings.

U.S. Securities and Exchange Commission Subpoenas

On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users in Africa, as well as revenue recognition relating to sales of products and services to end-users in Africa. We have also received, from time to time, requests in connection with the investigation to voluntarily produce additional information to the SEC, including information pertaining to certain other countries in Asia and Latin America.

We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it.

Department of Justice Grand Jury Subpoena

On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act.

We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it.

Securities Class Actions

On April 21, 2016, a class action lawsuit captioned Godinez v. Alere Inc., was filed against us in the United States District Court for the District of Massachusetts. On May 4, 2016, a second class action lawsuit captioned Breton v. Alere Inc., was filed against us in the United States District Court for the District of Massachusetts. Both of these class actions purport to assert claims against us and certain current and former officers for alleged violations of Section 10(b) and Section 20(a) of the Exchange Act and Rule 10b-5 under the Exchange Act. Each plaintiff seeks to represent a proposed class of all persons who purchased or otherwise acquired our common stock during the period May 9, 2013 through April 20, 2016. Each complaint seeks damages allegedly caused by alleged materially misleading statements and/or material omissions by us and the officers regarding our business, prospects and operations, each plaintiff claims, which allegedly operated to inflate artificially the price paid for our common stock during the class period. Each complaint seeks unspecified compensatory damages, attorneys’ fees and costs. On July 11, 2016, the court entered an order consolidating the two actions and appointing lead plaintiffs and lead counsel, and on July 19, 2016, the court ordered a schedule for the filing of a consolidated amended complaint and for the motion to dismiss briefing.

We are unable at this time to determine the outcome of this class action lawsuit or our potential liability, if any.

 

22


Table of Contents

Matters Relating to our San Diego Facility

On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out of the October 2012 warning letter could not occur until after a future inspection.

In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the government and are responding to the investigation, which is ongoing. We have been engaged in discussions with the government about this matter, including a resolution of potential related False Claims Act and common law liability exposure for the products under review. As a result of these discussions, management has accrued $10.2 million for this matter in the three months ended June 30, 2016. We would need to obtain certain approvals before we could agree to any proposed resolution. There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to or finalized. We may be required to engage in litigation of this matter, which may be time consuming and costly. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution, the ultimate amount of potential loss may materially exceed the accrual we have established.

We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them.

INRatio Class Actions

On May 26, 2016, a class action lawsuit captioned Dina Andren and Sidney Bludman v. Alere Inc., et al., was filed against us in the United States District Court for the Southern District of California. In addition, on July 22, 2016, a class action lawsuit captioned J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., was filed against us in the United States District Court for the District of Massachusetts. These class actions purport to assert claims against us under several legal theories, including fraud, breach of warranty, unjust enrichment and violation of applicable unfair competition/business practice statutes in connection with the manufacturing, marketing and sale of our INRatio products. The plaintiffs in the Dina Andren and Sidney Bludman class action seek to represent a proposed class of all persons who purchased, rented or otherwise paid for the INRatio system during the period January 1, 2009 to May 26, 2016 in the United States, or alternatively, California, Maryland and/or New York. The plaintiffs in the J.E, J.D., and all others similarly situated class action seek to represent a proposed class of all persons who purchased, rented or otherwise paid for the INRatio system during the period April 1, 2008 to present. Both class action complaints seek restitution and damages allegedly resulting from inaccurate PT/INR readings and from the purchase of devices that claimants say they would not have purchased had they known of the alleged propensity of these devices to yield inaccurate PT/INR results. Among other things, plaintiffs in these class action lawsuits seek a refund of money spent on INRatio products. Each complaint also seeks unspecified compensatory damages, injunctive relief, attorneys’ fees and costs. The Andren action also appears to seek damages for personal injury.

We are unable, at this time, to predict the outcome of these class action lawsuits.

Claims in the Ordinary Course and Other Matters

We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. In addition, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. We are cooperating with these investigations and are providing documents in response to both subpoenas. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, the most recent of which was received in July 2016, from the United States Attorney for the Middle District of Tennessee in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The CIDs request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence related to the same, dating back to January 2010. We are cooperating with the investigation and are providing documents responsive to the CIDs. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on Alere or its subsidiaries.

We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio System, including documents relating to prior interactions with the FDA and others regarding the system.

Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by private third-party payers, including health insurers, Zone Program Integrity Contractors, or ZPICs, and Medicare

 

23


Table of Contents

Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support or claims relating to the medical necessity of certain testing and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error.

Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above).

Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could adversely impact our business, results of operations, financial condition, and cash flows.

(18) Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt on or before the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. Please also see Note 3, Summary of Significant Accounting Policies, to our consolidated financial statements included within our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Recently Issued Standards

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, or ASU 2016-12. ASU 2016-12: (1) clarifies the objective of the collectability criterion for applying Accounting Standards Codification, or ASC, paragraph 606-10-25-7; (2) permits an entity to exclude amounts collected from customers for all sales (and other similar) taxes from the transaction price; (3) specifies that the measurement date for non-cash consideration is contract inception; (4) provides a practical expedient that permits an entity to reflect the aggregate effect of all modifications that occur before the beginning of the earliest period presented when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations; (5) clarifies that a completed contract for purposes of transition is a contract for which all (or substantially all) of the revenue was recognized under legacy GAAP before the date of initial application, and (6) clarifies that an entity that retrospectively applies the guidance in Topic 606 to each prior reporting period is not required to disclose the effect of the accounting change for the period of adoption. ASU 2016-12 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We do not expect the adoption of ASU 2016-12 to have a significant impact on our consolidated financial statements.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, or ASU 2016-10. ASU 2016-10 adds further guidance on identifying performance obligations and also to improve the operability and understandability of the licensing implementation guidance. ASU 2016-10 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU 2016-10 on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, or ASU 2016-09. ASU 2016-09 simplifies several aspects of the accounting for share-based payment award transactions including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. We do not expect the adoption of ASU 2016-09 to have a significant impact on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, or ASU 2016-07. ASU 2016-07 eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. ASU 2016-07 requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. Therefore, upon qualifying for the equity method of accounting, no retroactive adjustment of the investment is required. ASU 2016-07 also requires that an entity that has an available-for-sale equity security that becomes qualified for the equity method of accounting recognize through earnings the unrealized holding gain or loss in accumulated other comprehensive income at the date the investment becomes qualified for use of the equity method. ASU 2016-07 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and should be applied prospectively with early adoption permitted. We do not expect the adoption of ASU 2016-07 to have a significant impact on our consolidated financial statements.

 

24


Table of Contents

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), or ASU 2016-02. ASU 2016-02 requires lessees to recognize for all leases (with the exception of short-term leases) at the commencement date, a lease liability which is a lessee‘s obligation to make lease payments arising from a lease measured on a discounted basis, and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and should be applied with a modified retrospective transition approach, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU 2016-02 on our consolidated financial statements.

We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements.

Recently Adopted Standards

In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. ASU 2015-16 requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. ASU 2015-16 is effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively to adjustments to provisional amounts that occur after the effective date with earlier application permitted for financial statements that have not been issued. Effective January 1, 2016, we adopted ASU 2015-16. The adoption did not have a significant impact on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, or ASU 2015-03. ASU 2015-03 is intended to simplify the presentation of debt issuance costs. It requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. In August 2015, the FASB issued ASU No. 2015-15, Interest —Imputation of Interest (Subtopic 835-30) — Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting), or ASU 2015-15. ASU 2015-15 adds the authoritative guidance on presentation or subsequent measurement of debt issuance costs related to line-of-credit arrangements to ASU 2015-03. Effective December 31, 2015, we adopted ASU 2015-03 and ASU 2015-15, and accordingly we have reclassified $49.6 million and $34.1 million of debt issuance costs from other non-current assets to long-term debt, net of current portion on our balance sheet as of June 30, 2016 and December 31, 2015, respectively.

In June 2014, the FASB issued ASU No. 2014-12, Compensation — Stock Compensation (Topic 718) — Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, or ASU 2014-12. ASU 2014-12 requires that a performance target which affects vesting and which could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. Effective March 31, 2016, we adopted ASU 2014-12. The adoption did not have a significant impact on our consolidated financial statements.

(19) Equity Investments

We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments  Equity Method and Joint Ventures, based on the percentage of our ownership interest in the business. Our equity investments primarily include the following:

(a) SPD

We recorded earnings of $1.6 million and $6.2 million during the three and six months ended June 30, 2016, respectively, and earnings of $0.6 million and $4.2 million during the three and six months ended June 30, 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods and elimination of intercompany profit in inventory related to sales from Alere to SPD which is reflected in SPD’s net income. During the three and six months ended June 30, 2015, we received $12.1 million in cash from SPD as a return of capital.

 

25


Table of Contents

(b) TechLab

We recorded earnings of $0.6 million and $1.0 million during the three and six months ended June 30, 2016, respectively, and earnings of $0.4 million and $0.8 million during the three and six months ended June 30, 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our accompanying consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. During the three and six months ended June 30, 2015, we received $2.2 million in cash from TechLab as a return of capital.

As of June 30, 2016, we continued to meet the held for sale criteria with respect to our 49% investment in TechLab. We intend to use all or a portion of the proceeds from any sale of this investment to fund our working capital, operations, research and development or repay a portion of our outstanding indebtedness. Accordingly, we have classified our investment in TechLab in assets held for sale – non-current in our consolidated balance sheet as of June 30, 2016.

Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands):

 

     Three Months Ended June 30,      Six Months Ended June 30,  

Combined Condensed Results of Operations:

   2016      2015      2016      2015  

Net revenue

   $ 55,077       $ 53,159       $ 108,511       $ 101,016   
  

 

 

    

 

 

    

 

 

    

 

 

 

Gross profit

   $ 36,634       $ 34,559       $ 72,853       $ 67,830   
  

 

 

    

 

 

    

 

 

    

 

 

 

Net income after taxes

   $ 4,328       $ 3,039       $ 14,469       $ 11,096   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

Combined Condensed Balance Sheet:

   June 30, 2016      December 31, 2015  

Current assets

   $ 91,942       $ 71,542   

Non-current assets

     31,826         30,802   
  

 

 

    

 

 

 

Total assets

   $ 123,768       $ 102,344   
  

 

 

    

 

 

 

Current liabilities

   $ 47,764       $ 37,609   

Non-current liabilities

     5,845         5,157   
  

 

 

    

 

 

 

Total liabilities

   $ 53,609       $ 42,766   
  

 

 

    

 

 

 

(20) Impairment and (Gain) Loss on Dispositions, Net

In January 2016, we completed the sale of our Alere E-Santé business, which was a component of our professional diagnostics reporting unit and business segment. We received cash consideration of approximately $8.1 million, net of a final working capital adjustment totaling approximately $0.2 million, and we are eligible to receive up to $1.5 million of contingent cash consideration. As a result of this transaction, we recorded a $3.8 million gain in the three months ended March 31, 2016 on the disposition of the Alere E-Santé business.

In May 2015, we sold our Alere Analytics business, which was part of our professional diagnostics reporting unit and business segment. Under the terms of the sale we received nominal consideration and agreed to contribute working capital of $2.7 million to Alere Analytics, of which $2.4 million was contributed in cash immediately prior to the closing of the sale and the remaining $0.3 million of which was deposited in escrow pending the performance by the buyers under certain contracts. As a result of this transaction we recorded a loss of $4.7 million during the second quarter of 2015. During the three months ended March 31, 2015, before identifying a buyer for Alere Analytics, our management decided to close the business, and in connection with this decision we recorded an impairment charge of $26.7 million during the period, including the write-off of $26.2 million of acquisition-related intangible assets and $0.5 million of fixed assets.

In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during the three months ended March 31, 2015.

In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for €7.6 million (approximately $8.2 million at March 31, 2015) and, as a result of this transaction, we recorded a loss on disposition of $7.5 million during the three months ended March 31, 2015.

In December 2014, our management decided to close our Alere Connect, LLC subsidiary, which is part of our professional diagnostics reporting unit and business segment. During the six months ended June 30, 2015, in connection with this decision, we recorded impairment charges of $1.0 million, consisting primarily of severance costs, inventory write-offs and other closure-related expenses.

The financial results for the above businesses are immaterial to our consolidated financial results.

 

26


Table of Contents

(21) Income Taxes

We determine our estimated annual effective tax rate at the end of each interim period based on forecasted full-year pre-tax income (loss) by jurisdiction and permanent items. Our effective tax rate by quarter may vary based on actual quarter to date income and the forecasted mix of jurisdictional income (loss), as well as discrete items.

A reconciliation between the U.S. federal statutory rate and our effective tax rate is summarized as follows:

 

     For the Three Months Ended
June 30,
    For the Six Months Ended
June 30,
 
     2016     2015     2016     2015  

Statutory rate

     35     35     35     35

State income taxes, net of federal benefit

     (5)     (4)     (4)     (5)

Rate differential on foreign earnings

     (61)     (19)     (58)     (27)

Change in valuation allowance

     (4)     (3)     (6)     10

Stock-based compensation

     11     5     11     (9)

Uncertain tax positions

     12     7     9     15

Disposition of BBI

     0     27     0     65

Other

     3     6     7     (12)
  

 

 

   

 

 

   

 

 

   

 

 

 

Effective tax rate

     (9 )%      54     (6 )%      72
  

 

 

   

 

 

   

 

 

   

 

 

 

For the three months and six months ended June 30, 2016, compared to the same periods in 2015, our effective tax rate decrease is primarily attributed to a more favorable jurisdictional mix of income and losses in the current year and non-recurring discrete tax impacts in 2015.

(22) Guarantor Financial Information

Our 7.25% senior notes due 2018, our 6.5% senior subordinated notes due 2020 and our 6.375% senior subordinated notes due 2023 are guaranteed, and before their redemption on October 1, 2015, our 8.625% senior subordinated notes due 2018 were guaranteed, by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of June 30, 2016 and December 31, 2015, the related statements of operations and statements of comprehensive income (loss) for the three and six months ended June 30, 2016 and 2015, and statements of cash flows for the six months ended June 30, 2016 and 2015, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting.

We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties.

Effective December 31, 2015, we adopted ASU 2015-03 and ASU 2015-15, and accordingly we have reclassified $49.6 million and $34.1 million of debt issuance costs from other non-current assets to long-term debt, net of current portion on our balance sheet as of June 30, 2016 and December 31, 2015, respectively, as described in Note 18 Recent Accounting Pronouncements.

As discussed in Note 2 Revision to Previously Reported Financial Statements, in connection with the preparation of our consolidated financial statements for 2015, we determined that, in 2013 and 2014, each of the interim periods in 2014, and the first three quarters of 2015, we had incorrectly recorded the revenue for such periods. In addition, we corrected several out-of-period adjustments. As a result, we revised our consolidated financial information for the years ended December 31, 2014 and 2013, each of the interim periods in 2014 and the first three quarters of 2015. The revisions to the consolidating statements of cash flows in this Note 22 did not impact previously reported net cash flows from operating activities, investing activities, or financing activities and as a result, there was no net impact to net change in cash and cash equivalents for the previously reported periods reflected in this Note 22.

 

27


Table of Contents

The following schedules reconcile the amounts as previously reported in our consolidating financial statements to the corresponding revised amounts:

 

     Three Months Ended June 30, 2015  

Revised Consolidating Statement of Operations- Guarantor Subsidiaries

(in thousands)

   As Previously
Reported
     Revision
Adjustment
     As
Revised
 

Net revenue

   $ 330,820       $ (1,011    $ 329,809   

Cost of net revenue

   $ 199,233       $ 14       $ 199,247   

Income from continuing operations before benefit for income taxes

   $ 55,133       $ (2,090    $ 53,043   

Provision for income taxes

   $ 11,277       $ (447    $ 10,830   

Income from continuing operations

   $ 43,856       $ (1,643    $ 42,213   
     Three Months Ended June 30, 2015  

Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries

(in thousands)

   As Previously
Reported
     Revision
Adjustment
     As
Revised
 

Net revenue

   $ 367,418       $ (4,774    $ 362,644   

Cost of net revenue

   $ 205,840       $ (559    $ 205,281   

Income from continuing operations before benefit for income taxes

   $ 111,130       $ (5,415    $ 105,715   

Provision for income taxes

   $ 22,768       $ (1,565    $ 21,203   

Income from continuing operations

   $ 88,786       $ (3,850    $ 84,936   
     Six Months Ended June 30, 2015  

Revised Consolidating Statement of Operations- Guarantor Subsidiaries

(in thousands)

   As Previously
Reported
     Revision
Adjustment
     As
Revised
 

Net revenue

   $ 659,282       $ (3,181    $ 656,101   

Cost of net revenue

   $ 387,269       $ (882    $ 386,387   

Income from continuing operations before benefit for income taxes

   $ 60,049       $ (4,461    $ 55,588   

Provision for income taxes

   $ 13,097       $ (1,516    $ 11,581   

Income from continuing operations

   $ 46,952       $ (2,945    $ 44,007   
     Six Months Ended June 30, 2015  

Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries

(in thousands)

   As Previously
Reported
     Revision
Adjustment
     As
Revised
 

Net revenue

   $ 710,777       $ 2,135       $ 712,912   

Cost of net revenue

   $ 398,325       $ 1,846       $ 400,171   

Income from continuing operations before benefit for income taxes

   $ 188,294       $ (911    $ 187,383   

Provision for income taxes

   $ 32,483       $ 437       $ 32,920   

Income from continuing operations

   $ 159,803       $ (1,348    $ 158,455   

 

28


Table of Contents

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended June 30, 2016

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net product sales

   $ —        $ 222,954      $ 335,540      $ (74,748   $ 483,746   

Services revenue

     —          112,698        12,111        —          124,809   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

     —          335,652        347,651        (74,748     608,555   

License and royalty revenue

     —          3,448        2,008        (2,923     2,533   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     —          339,100        349,659        (77,671     611,088   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

     220        126,795        188,478        (65,095     250,398   

Cost of services revenue

     104        79,203        7,760        (8,773     78,294   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

     324        205,998        196,238        (73,868     328,692   

Cost of license and royalty revenue

     —          (7     3,466        (2,924     535   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

     324        205,991        199,704        (76,792     329,227   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

     (324     133,109        149,955        (879     281,861   

Operating expenses:

          

Research and development

     2,997        16,194        9,255        —          28,446   

Sales and marketing

     1,568        53,155        47,793        —          102,516   

General and administrative

     57,740        30,460        40,154        —          128,354   

Impairment and (gain) loss on dispositions, net

     —          —          —          —          —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     (62,629     33,300        52,753        (879     22,545   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (41,857     (2,223     (2,775     4,526        (42,329

Other income (expense), net

     (8,144     4,103        (5,544     (4,527     (14,112
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before provision (benefit) for income taxes

     (112,630     35,180        44,434        (880     (33,896

Provision (benefit) for income taxes

     19,765        (6,759     (9,889     —          3,117   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax

     (132,395     41,939        54,323        (880     (37,013

Equity in earnings of subsidiaries, net of tax

     96,916        —          —          (96,916     —     

Equity earnings of unconsolidated entities, net of tax

     588        —          1,557        (23     2,122   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

     (34,891     41,939        55,880        (97,819     (34,891

Less: Net income attributable to non-controlling interests

     —          —          143        —          143   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to Alere Inc. and Subsidiaries 

     (34,891     41,939        55,737        (97,819     (35,034

Preferred stock dividends

     (5,308     —          —          —          (5,308
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) available to common stockholders 

   $ (40,199   $ 41,939      $ 55,737      $ (97,819   $ (40,342
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

29


Table of Contents

CONSOLIDATING STATEMENT OF OPERATIONS

For the Three Months Ended June 30, 2015

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net product sales

   $ —        $ 211,593      $ 345,289      $ (65,833   $ 491,049   

Services revenue

     —          114,983        11,645        —          126,628   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

     —          326,576        356,934        (65,833     617,677   

License and royalty revenue

     —          3,233        5,710        (3,249     5,694   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     —          329,809        362,644        (69,082     623,371   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

     417        120,953        193,593        (57,070     257,893   

Cost of services revenue

     80        77,884        7,524        (8,688     76,800   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

     497        198,837        201,117        (65,758     334,693   

Cost of license and royalty revenue

     19        410        4,164        (3,249     1,344   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

     516        199,247        205,281        (69,007     336,037   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

     (516     130,562        157,363        (75     287,334   

Operating expenses:

          

Research and development

     3,241        13,993        9,964        —          27,198   

Sales and marketing

     1,570        52,101        54,353        —          108,024   

General and administrative

     24,390        51,288        (14,505     —          61,173   

Impairment and (gain) loss on dispositions, net

     44,378        (39,412     576        —          5,542   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     (74,095     52,592        106,975        (75     85,397   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (59,086     (3,060     (4,702     7,354        (59,494

Other income (expense), net

     3,596        3,511        3,442        (7,354     3,195   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before provision (benefit) for income taxes

     (129,585     53,043        105,715        (75     29,098   

Provision (benefit) for income taxes

     (16,306     10,830        21,203        (38     15,689   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax

     (113,279     42,213        84,512        (37     13,409   

Equity in earnings of subsidiaries, net of tax

     127,127        —          —          (127,127     —     

Equity earnings of unconsolidated entities, net of tax

     922        —          424        15        1,361   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     14,770        42,213        84,936        (127,149     14,770   

Less: Net income attributable to non-controlling interests

     —          —          359        —          359   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Alere Inc. and Subsidiaries

     14,770        42,213        84,577        (127,149     14,411   

Preferred stock dividends

     (5,308     —          —          —          (5,308
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income available to common stockholders

   $ 9,462      $ 42,213      $ 84,577      $ (127,149   $ 9,103   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

30


Table of Contents

CONSOLIDATING STATEMENT OF OPERATIONS

For the Six Months Ended June 30, 2016

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net product sales

   $ —        $ 447,334      $ 632,377      $ (136,194   $ 943,517   

Services revenue

     —          217,182        23,336        —          240,518   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

     —          664,516        655,713        (136,194     1,184,035   

License and royalty revenue

     —          6,368        4,566        (5,672     5,262   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     —          670,884        660,279        (141,866     1,189,297   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

     334        251,553        354,460        (118,488     487,859   

Cost of services revenue

     104        151,698        15,800        (16,208     151,394   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

     438        403,251        370,260        (134,696     639,253   

Cost of license and royalty revenue

     —          10        7,589        (5,673     1,926   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

     438        403,261        377,849        (140,369     641,179   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

     (438     267,623        282,430        (1,497     548,118   

Operating expenses:

          

Research and development

     7,131        30,653        17,724        —          55,508   

Sales and marketing

     2,904        107,620        91,805        —          202,329   

General and administrative

     102,355        63,646        77,309        —          243,310   

Impairment and (gain) loss on dispositions, net

     —          —          (3,810     —          (3,810
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     (112,828     65,704        99,402        (1,497     50,781   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (82,944     (4,875     (5,842     9,226        (84,435

Other income (expense), net

     (6,156     6,605        (6,683     (9,227     (15,461
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before provision (benefit) for income taxes

     (201,928     67,434        86,877        (1,498     (49,115

Provision (benefit) for income taxes

     19,711        (6,509     (10,293     —          2,909   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax

     (221,639     73,943        97,170        (1,498     (52,024

Equity in earnings of subsidiaries, net of tax

     175,502        —          —          (175,502     —     

Equity earnings of unconsolidated entities, net of tax

     1,269        —          6,138        (251     7,156   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss)

     (44,868     73,943        103,308        (177,251     (44,868

Less: Net income attributable to non-controlling interests

     —          —          246        —          246   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) attributable to Alere Inc. and Subsidiaries

     (44,868     73,943        103,062        (177,251     (45,114

Preferred stock dividends

     (10,617     —          —          —          (10,617
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) available to common stockholders

   $ (55,485   $ 73,943      $ 103,062      $ (177,251   $ (55,731
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

31


Table of Contents

CONSOLIDATING STATEMENT OF OPERATIONS

For the Six Months Ended June 30, 2015

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net product sales

   $ —        $ 426,631      $ 675,395      $ (126,639   $ 975,387   

Services revenue

     —          223,040        27,444        —          250,484   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net product sales and services revenue

     —          649,671        702,839        (126,639     1,225,871   

License and royalty revenue

     —          6,430        10,073        (6,111     10,392   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net revenue

     —          656,101        712,912        (132,750     1,236,263   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales

     833        233,248        375,999        (112,086     497,994   

Cost of services revenue

     130        151,921        15,964        (15,589     152,426   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net product sales and services revenue

     963        385,169        391,963        (127,675     650,420   

Cost of license and royalty revenue

     (21     1,218        8,208        (6,111     3,294   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cost of net revenue

     942        386,387        400,171        (133,786     653,714   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit (loss)

     (942     269,714        312,741        1,036        582,549   

Operating expenses:

          

Research and development

     5,543        28,912        20,759        —          55,214   

Sales and marketing

     2,830        105,328        108,945        —          217,103   

General and administrative

     44,913        89,058        19,893        —          153,864   

Impairment and (gain) loss on dispositions, net

     80,901        (8,804     (31,763     —          40,334   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     (135,129     55,220        194,907        1,036        116,034   

Interest expense, including amortization of original issue discounts and deferred financing costs

     (105,184     (6,345     (8,745     14,349        (105,925

Other income (expense), net

     7,243        6,713        1,221        (14,349     828   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before provision (benefit) for income taxes

     (233,070     55,588        187,383        1,036        10,937   

Provision (benefit) for income taxes

     (36,973     11,581        32,920        308        7,836   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax

     (196,097     44,007        154,463        728        3,101   

Equity in earnings of subsidiaries, net of tax

     201,260        —          —          (201,260     —     

Equity earnings of unconsolidated entities, net of tax

     1,346        —          3,992        (18     5,320   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     6,509        44,007        158,455        (200,550     8,421   

Income (loss) from discontinued operations, net of tax

     218,689        (1,912     —          —          216,777   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     225,198        42,095        158,455        (200,550     225,198   

Less: Net income attributable to non-controlling interests

     —          —          447        —          447   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Alere Inc. and Subsidiaries

     225,198        42,095        158,008        (200,550     224,751   

Preferred stock dividends

     (10,558     —          —          —          (10,558
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net income available to common stockholders

   $ 214,640      $ 42,095      $ 158,008      $ (200,550   $ 214,193   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

32


Table of Contents

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended June 30, 2016

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-
Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net income (loss)

   $ (34,891   $ 41,939      $ 55,880      $ (97,819   $ (34,891
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax:

          

Changes in cumulative translation adjustment

     276        (699     (43,720     8        (44,135

Minimum pension liability adjustment

     —          —          531        —          531   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax

     276        (699     (43,189     8        (43,604
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     276        (699     (43,189     8        (43,604
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (34,615     41,240        12,691        (97,811     (78,495

Less: Comprehensive income attributable to non-controlling interests

     —          —          143        —          143   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries

   $ (34,615   $ 41,240      $ 12,548      $ (97,811   $ (78,638
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

33


Table of Contents

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Three Months Ended June 30, 2015

(in thousands)

 

     Issuer      Guarantor
Subsidiaries
     Non-
Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net income

   $ 14,770       $ 42,213       $ 84,936      $ (127,149   $ 14,770   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive income, before tax:

            

Changes in cumulative translation adjustment

     197         689         45,840        —          46,726   

Minimum pension liability adjustment

     —           —           (374     —          (374
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive income, before tax

     197         689         45,466        —          46,352   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive income

     197         689         45,466        —          46,352   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income

     14,967         42,902         130,402        (127,149     61,122   

Less: Comprehensive income attributable to non-controlling interests

     —           —           359        —          359   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to Alere Inc. and Subsidiaries

   $ 14,967       $ 42,902       $ 130,043      $ (127,149   $ 60,763   
  

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

34


Table of Contents

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Six Months Ended June 30, 2016

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-
Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net income (loss)

   $ (44,868   $ 73,943      $ 103,308      $ (177,251   $ (44,868
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax:

          

Changes in cumulative translation adjustment

     391        (828     (21,513     8        (21,942

Minimum pension liability adjustment

     —          —          686        —          686   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax

     391        (828     (20,827     8        (21,256
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     391        (828     (20,827     8        (21,256
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (44,477     73,115        82,481        (177,243     (66,124

Less: Comprehensive income attributable to non-controlling interests

     —          —          246        —          246   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries

   $ (44,477   $ 73,115      $ 82,235      $ (177,243   $ (66,370
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

35


Table of Contents

CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS)

For the Six Months Ended June 30, 2015

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
     Non-
Guarantor
Subsidiaries
    Eliminations     Consolidated  

Net income

   $ 225,198      $ 42,095       $ 158,455      $ (200,550   $ 225,198   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax:

           

Changes in cumulative translation adjustment

     (460     117         (33,273     —          (33,616

Minimum pension liability adjustment

     —          —           (1,756     —          (1,756
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), before tax

     (460     117         (35,029     —          (35,372
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss)

     (460     117         (35,029     —          (35,372
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income

     224,738        42,212         123,426        (200,550     189,826   

Less: Comprehensive income attributable to non-controlling interests

     —          —           447        —          447   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income attributable to Alere Inc. and Subsidiaries

   $ 224,738      $ 42,212       $ 122,979      $ (200,550   $ 189,379   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

 

36


Table of Contents

CONSOLIDATING BALANCE SHEET

June 30, 2016

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
     Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

ASSETS

           

Current assets:

           

Cash and cash equivalents

   $ 49,465      $ 6,881       $ 449,818      $ —        $ 506,164   

Restricted cash

     1,415        —           4,247        —          5,662   

Marketable securities

     —          74         —          —          74   

Accounts receivable, net of allowances

     —          190,438         236,784        —          427,222   

Inventories, net

     —          168,413         188,448        (23,015     333,846   

Deferred tax assets

     (455     6,513         (6,058     —          —     

Prepaid expenses and other current assets

     12,194        33,489         110,122        6,534        162,339   

Intercompany receivables

     360,548        827,927         158,858        (1,347,333     —     
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total current assets

     423,167        1,233,735         1,142,219        (1,363,814     1,435,307   

Property, plant and equipment, net

     29,742        224,796         187,337        (3,088     438,787   

Goodwill

     —          1,823,018         988,527        —          2,811,545   

Other intangible assets with indefinite lives

     —          7,538         20,800        (59     28,279   

Finite-lived intangible assets, net

     2,745        566,973         342,690        (3,200     909,208   

Restricted cash

     —          —           42,589        —          42,589   

Other non-current assets

     570        2,052         14,317        (649     16,290   

Investments in subsidiaries

     3,455,642        158,195         57,650        (3,671,487     —     

Investments in unconsolidated entities

     687        14,765         44,654        14,405        74,511   

Deferred tax assets

     (66,034     24,785         62,006        (2,119     18,638   

Non-current income tax receivable

     3,517        —           —          —          3,517   

Assets held for sale — non-current

     12,223        —           —          —          12,223   

Intercompany notes receivables

     1,887,589        708,708         2,901        (2,599,198     —     
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total assets

   $ 5,749,848      $ 4,764,565       $ 2,905,690      $ (7,629,209   $ 5,790,894   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

LIABILITIES AND EQUITY

           

Current liabilities:

           

Short-term debt and current portion of long-term debt

   $ 40,073      $ —         $ 3,608      $ —        $ 43,681   

Current portion of capital lease obligations

     —          1,654         1,846        —          3,500   

Accounts payable

     23,789        77,283         93,163        —          194,235   

Accrued expenses and other current liabilities

     (514,898     635,590         197,663        2,171        320,526   

Intercompany payables

     965,315        178,406         203,621        (1,347,342     —     
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total current liabilities

     514,279        892,933         499,901        (1,345,171     561,942   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Long-term liabilities:

           

Long-term debt, net of current portion

     2,874,825        —           45,964        —          2,920,789   

Capital lease obligations, net of current portion

     —          1,466         5,506        —          6,972   

Deferred tax liabilities

     (158,407     250,292         48,897        82        140,864   

Other long-term liabilities

     14,741        56,618         77,455        (649     148,165   

Intercompany notes payables

     496,756        1,162,748         939,694        (2,599,198     —     
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total long-term liabilities

     3,227,915        1,471,124         1,117,516        (2,599,765     3,216,790   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total stockholders’ equity

     2,007,654        2,400,508         1,283,765        (3,684,273     2,007,654   

Non-controlling interests

     —          —           4,508        —          4,508   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total equity

     2,007,654        2,400,508         1,288,273        (3,684,273     2,012,162   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

Total liabilities and equity

   $ 5,749,848      $ 4,764,565       $ 2,905,690      $ (7,629,209   $ 5,790,894   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

 

 

37


Table of Contents

CONSOLIDATING BALANCE SHEET

December 31, 2015

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
     Eliminations     Consolidated  

ASSETS

           

Current assets:

           

Cash and cash equivalents

   $ 139,153      $ 21,150      $ 341,897       $ —        $ 502,200   

Restricted cash

     1,250        —          4,444         —          5,694   

Marketable securities

     —          164        —           —          164   

Accounts receivable, net of allowances

     —          192,591        253,242         —          445,833   

Inventories, net

     —          173,383        194,192         (20,574     347,001   

Deferred tax assets

     (52,410     31,285        23,244         (2,119     —     

Prepaid expenses and other current assets

     7,575        27,095        110,961         6,602        152,233   

Assets held for sale — current

     —          —          4,165         —          4,165   

Intercompany receivables

     620,838        812,957        50,691         (1,484,486     —     
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total current assets

     716,406        1,258,625        982,836         (1,500,577     1,457,290   

Property, plant and equipment, net

     31,384        228,065        188,084         (1,494     446,039   

Goodwill

     —          1,823,919        1,012,996         —          2,836,915   

Other intangible assets with indefinite lives

     —          7,638        20,531         (59     28,110   

Finite-lived intangible assets, net

     2,951        627,269        370,261         (3,200     997,281   

Restricted cash

     —          —          43,228         —          43,228   

Other non-current assets

     804        2,340        15,380         (446     18,078   

Investments in subsidiaries

     3,294,857        158,195        57,650         (3,510,702     —     

Investments in unconsolidated entities

     502        14,764        37,947         12,120        65,333   

Deferred tax assets

     (14,078     (14     28,085         —          13,993   

Non-current income tax receivable

     3,517        —          —           —          3,517   

Assets held for sale — non-current

     13,337        —          —           —          13,337   

Intercompany notes receivables

     1,905,188        672,032        6,900         (2,584,120     —     
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total assets

   $ 5,954,868      $ 4,792,833      $ 2,763,898       $ (7,588,478   $ 5,923,121   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

LIABILITIES AND EQUITY

           

Current liabilities:

           

Short-term debt and current portion of long-term debt

   $ 197,084      $ —        $ 2,908       $ —        $ 199,992   

Current portion of capital lease obligations

     —          2,018        1,944         —          3,962   

Accounts payable

     15,981        76,890        102,881         —          195,752   

Accrued expenses and other current liabilities

     (554,350     650,632        225,944         2,239        324,465   

Liabilities related to assets held for sale — current

     —          —          363         —          363   

Intercompany payables

     1,122,042        249,553        112,891         (1,484,486     —     
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total current liabilities

     780,757        979,093        446,931         (1,482,247     724,534   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Long-term liabilities:

           

Long-term debt, net of current portion

     2,784,913        —          46,253         —          2,831,166   

Capital lease obligations, net of current portion

     —          840        6,341         —          7,181   

Deferred tax liabilities

     (157,708     250,495        54,749         82        147,618   

Other long-term liabilities

     14,962        59,309        80,369         (447     154,193   

Intercompany notes payables

     477,779        1,181,168        925,173         (2,584,120     —     
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total long-term liabilities

     3,119,946        1,491,812        1,112,885         (2,584,485     3,140,158   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total stockholders’ equity

     2,054,165        2,321,928        1,199,818         (3,521,746     2,054,165   

Non-controlling interests

     —          —          4,264         —          4,264   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total equity

     2,054,165        2,321,928        1,204,082         (3,521,746     2,058,429   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Total liabilities and equity

   $ 5,954,868      $ 4,792,833      $ 2,763,898       $ (7,588,478   $ 5,923,121   
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

 

38


Table of Contents

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2016

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

Cash Flows from Operating Activities:

          

Net income (loss)

   $ (44,868   $ 73,943      $ 103,308      $ (177,251   $ (44,868

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

          

Equity in earnings of subsidiaries, net of tax

     (175,502     —          —          175,502        —     

Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

     5,175        7        79        —          5,261   

Depreciation and amortization

     4,484        88,973        48,109        839        142,405   

Non-cash stock-based compensation expense

     10,541        5,462        4,604        —          20,607   

Impairment of inventory

     —          —          870        —          870   

Impairment of long-lived assets

     —          548        85        —          633   

Loss on disposition of fixed assets

     1        3,522        712        —          4,235   

Equity earnings of unconsolidated entities, net of tax

     (1,269     —          (6,138     251        (7,156

Deferred income taxes

     —          (200     (13,010     —          (13,210

(Gain) loss related to impairment and net (gain) loss on dispositions

     —          —          (3,810     —          (3,810

Other non-cash items

     (66     459        9,323        4        9,720   

Non-cash change in fair value of contingent purchase price consideration

     (800     (823     (157     —          (1,780

Changes in assets and liabilities, net of acquisitions:

          

Accounts receivable, net

     —          2,141        17,882        —          20,023   

Inventories, net

     —          (11,723     5,243        660        (5,820

Prepaid expenses and other current assets

     (4,283     (7,408     (13,258     68        (24,881

Accounts payable

     7,807        396        (8,204     —          (1

Accrued expenses and other current liabilities

     40,481        (13,721     (28,367     (69     (1,676

Other non-current liabilities

     (1,054     (1,561     (3,491     —          (6,106

Cash paid for contingent consideration

     (321     —          (3     —          (324

Intercompany payable (receivable)

     145,358        (141,518     (3,836     (4     —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     (14,316     (1,503     109,941        —          94,122   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Investing Activities:

          

Increase in restricted cash

     (165     —          (284     —          (449

Purchases of property, plant and equipment

     (2,680     (11,750     (18,972     1,084        (32,318

Proceeds from sale of property, plant and equipment

     92        45        1,839        (1,084     892   

Cash received from (used in) dispositions, net of cash divested

     (1,337     —          22,807        —          21,470   

Cash paid for business acquisitions, net of cash acquired

     —          —          (5,958     —          (5,958

Cash received from equity method investments

     2,383        —          —          —          2,383   

Cash received from sales of marketable securities.

     —          90        —          —          90   

Cash paid for investments

     (184     —          —          —          (184

(Increase) decrease in other assets

     (50     13        532        —          495   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     (1,941     (11,602     (36     —          (13,579
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Financing Activities:

          

Cash paid for financing costs

     (19,564     —          —          —          (19,564

Cash paid for contingent purchase price consideration

     —          —          (485     —          (485

Proceeds from issuance of common stock, net of issuance costs

     11,124        —          —          —          11,124   

Proceeds from issuance of long-term debt

     —          —          381        —          381   

Payments on short-term debt

     —          —          (791     —          (791

Payments on long-term debt

     (176,861     —          (776     —          (177,637

Net proceeds under revolving credit facilities

     125,000        —          1,213        —          126,213   

Cash paid for dividends

     (10,646     —          —          —          (10,646

Principal payments on capital lease obligations

     —          (1,324     (886     —          (2,210
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in financing activities

     (70,947     (1,324     (1,344     —          (73,615
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Foreign exchange effect on cash and cash equivalents

     (2,484     160        (640     —          (2,964
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     (89,688     (14,269     107,921        —          3,964   

Cash and cash equivalents, beginning of period

     139,153        21,150        341,897        —          502,200   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents, end of period

   $ 49,465      $ 6,881      $ 449,818      $ —        $ 506,164   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

39


Table of Contents

CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2015

(in thousands)

 

     Issuer     Guarantor
Subsidiaries
    Non-Guarantor
Subsidiaries
    Eliminations     Consolidated  

Cash Flows from Operating Activities:

          

Net income

   $ 225,198      $ 42,095      $ 158,455      $ (200,550   $ 225,198   

Income (loss) from discontinued operations, net of tax

     218,689        (1,912     —          —          216,777   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income from continuing operations

     6,509        44,007        158,455        (200,550     8,421   

Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities:

          

Equity in earnings of subsidiaries, net of tax

     (201,260     —          —          201,260        —     

Non-cash interest expense, including amortization of original issue discounts and deferred financing costs

     7,728        13        43        —          7,784   

Depreciation and amortization

     3,840        82,576        60,652        35        147,103   

Non-cash stock-based compensation expense

     6,458        2,633        3,188        —          12,279   

Impairment of inventory

     —          133        (65     —          68   

Impairment of long-lived assets

     —          64        323        —          387   

Loss on disposition of fixed assets

     —          2,764        554        —          3,318   

Equity earnings of unconsolidated entities, net of tax

     (1,346     —          (3,992     18        (5,320

Gain on sales of marketable securities

     —          (8     —          —          (8

Deferred income taxes

     (8,686     (32,097     (1,826     438        (42,171

(Gain) loss related to impairment and net (gain) loss on dispositions

     80,901        (8,804     (31,763     —          40,334   

Loss on extinguishment of debt

     3,480        —          —          —          3,480   

Other non-cash items

     (159     (1,497     (676     —          (2,332

Non-cash change in fair value of contingent purchase price consideration

     (30,895     15,748        (37,720     —          (52,867

Changes in assets and liabilities, net of acquisitions:

          

Accounts receivable, net

     —          (2,599     (15,417     —          (18,016

Inventories, net

     —          (27,824     (15,984     (1,411     (45,219

Prepaid expenses and other current assets

     (3,052     (19,127     810        (5,708     (27,077

Accounts payable

     (7,499     (11,331     (4,421     —          (23,251

Accrued expenses and other current liabilities

     (8,944     61,472        (33,374     3,898        23,052   

Other non-current liabilities

     2,226        6,171        (1,476     1,615        8,536   

Cash paid for contingent purchase price consideration

     (3,768     —          (13     —          (3,781

Intercompany payable (receivable)

     127,569        (101,515     (26,054     —          —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) continuing operations

     (26,898     10,779        51,244        (405     34,720   

Net cash provided by discontinued operations

     —          318        —          —          318   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) operating activities

     (26,898     11,097        51,244        (405     35,038   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Investing Activities:

          

Increase in restricted cash

     (422,169     —          (1,856     —          (424,025

Purchases of property, plant and equipment

     (5,147     (19,386     (23,907     1,156        (47,284

Proceeds from sale of property, plant and equipment

     —          738        1,199        (817     1,120   

Cash received from (used in) disposition, net of cash divested

     593,217        (8,723     2,131        —          586,625   

Cash received from equity method investments

     2,205        —          12,092        —          14,297   

Cash received from sales of marketable securities

     —          93        —          —          93   

Decrease in other assets

     348        409        927        66        1,750   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) continuing operations

     168,454        (26,869     (9,414     405        132,576   

Net cash used in discontinued operations

     —          (209     —          —          (209
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     168,454        (27,078     (9,414     405        132,367   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash Flows from Financing Activities:

          

Cash paid for financing costs

     (15,731     —          —          —          (15,731

Cash paid for contingent purchase price consideration

     (5,503     —          (870     —          (6,373

Proceeds from issuance of common stock, net of issuance costs

     56,332        —          —          —          56,332   

Proceeds from issuance of long-term debt

     2,119,125        —          2,726        —          2,121,851   

Payments on short-term debt

     —          —          (584     —          (584

Payments on long-term debt

     (2,117,875     —          (389     —          (2,118,264

Net payments under revolving credit facilities

     (127,000     —          680        —          (126,320

Cash paid for dividends

     (10,646     —          —          —          (10,646

Principal payments on capital lease obligations

     —          (1,263     (1,647     —          (2,910
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in continuing operations

     (101,298     (1,263     (84     —          (102,645

Net cash used in discontinued operations

     —          (76     —          —          (76
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in financing activities

     (101,298     (1,339     (84     —          (102,721
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Foreign exchange effect on cash and cash equivalents

     —          (129     (1,445     —          (1,574
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     40,258        (17,449     40,301        —          63,110   

Cash and cash equivalents, beginning of period — continuing operations

     2,149        69,154        307,158        —          378,461   

Cash and cash equivalents, beginning of period — discontinued operations

     —          23,300        —          —          23,300   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents of continuing operations, end of period

   $ 42,407      $ 75,005      $ 347,459      $ —        $ 464,871   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

40


Table of Contents

(23) Subsequent Events

Amendment to Credit Facility

As further described in Note 12 above, in August 2016 we entered into an amendment to our Credit Agreement.

INRatio and INRatio®2 PT/INR Monitoring System Voluntary Withdrawal

In July 2016 we announced that we will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 PT/INR Monitoring System. We are currently working with the FDA on implementing the product withdrawal and eventual product discontinuation.

In December 2014, we initiated a voluntary correction to inform users of the Alere INRatio and INRatio2 PT/INR Monitoring Systems that patients with certain medical conditions should not be tested with the systems. We proactively reported these device concerns to the FDA and began conducting a thorough investigation into these events.

Over the course of the past two years, Alere invested in the research and development of software enhancements intended to address the potential, in certain cases, of the system to deliver a result that differs from that of another measurement method.

We submitted the software enhancements to the FDA at the end of 2015. The FDA notified us that it believes that our studies do not adequately demonstrate the effectiveness of the software modification and advised us to submit a proposed plan to voluntarily remove the INRatio® device from the market.

In light of this input from the FDA and our business considerations, in July 2016 we determined to voluntarily remove the INRatio systems from the market.

Due to the fact that the circumstances giving rise to the voluntary withdrawal in the United States and related action outside the U.S. existed as of December 31, 2015, certain charges incurred in connection with the withdrawal were recorded in the fourth quarter of 2015. Specifically, we recorded a charge of approximately $38 million in the year ended December 31, 2015, related to impairment of inventory and production equipment and estimated costs of removing our INRatio and INRatio2 from the market. As of June 30, 2016, $16.0 million of the estimated costs of removing INRatio and INRatio 2 from the market were included in accrued expenses. Additionally, our decision to withdraw the INRatio and INRatio2 PT/INR Monitoring Systems impacted the useful life assumptions of certain tangible and intangible assets. As a result of this change in estimate, we recorded approximately $4.1 million and $8.2 million of accelerated amortization of intangible assets and approximately $0.8 million and $1.5 million of accelerated depreciation of tangible assets in the three and six months ended June 30, 2016, respectively. Finally, during the remainder of fiscal year 2016 we expect to incur approximately $8.2 million of accelerated amortization, approximately $1.6 million of accelerated depreciation, and $2.0 million of other one-time cash expenditures.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these statements by forward-looking words such as “may,” “could,” “should,” “would,” “intend,” “will,” “expect,” “anticipate,” “believe,” “estimate,” “continue” or similar words. You should read statements that contain these words carefully because they discuss our future expectations, contain projections of our future results of operations or of our financial condition or state other “forward-looking” information. Forward-looking statements include, without limitation, statements regarding the expected closing of, and the Company’s confidence with respect to the closing of, the transactions contemplated by the Merger Agreement with Abbott Laboratories, the benefits of our improved products, our plans to voluntarily withdraw the INRatio and INRatio2 PT/INR Monitoring Systems from the market, future competition in our markets, the implementation and effectiveness of efforts to remediate our material weaknesses, the outcome of certain tax examinations, the timing of decisions and the outcome of certain legal proceedings to which we and other parties are or may be subject, the sources of funds to pay the principal and interest on our indebtedness and certain expenses, intention to retain earnings to support our growth strategy, future trends with respect to license and royalty revenues, future trends with respect to amortization expense, the source of funds and the expected ability to fund short and long-term working capital needs, the anticipated use of proceeds from divestitures, future plans with respect to the repatriation of cash held by foreign entities, future litigation being brought against us and the impact of such litigation, the expected impact of recently announced and adopted accounting standards and other accounting standards on our financial statements, anticipated increases or decreases to certain tax benefits, expected future expenses in connection with the voluntary withdrawal of INRatio products from the market, anticipated expenses and costs in connection with certain restructuring plans, future charges in connection with a withdrawal of a product from the market, potential new product and technology achievements and the potential for selective divestitures of non-core assets. Actual results or developments could differ materially from those projected in such

 

41


Table of Contents

statements as a result of numerous factors, including, without limitation, those risks and uncertainties set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2015 and other risk factors identified herein or from time to time in our periodic filings with the SEC. We do not undertake any obligation to update any forward-looking statements unless required by law. This report and, in particular, the following discussion and analysis of our financial condition and results of operations, should be read in light of those risks and uncertainties and in conjunction with our accompanying consolidated financial statements and notes thereto.

Overview

We deliver reliable and actionable health information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes globally. Our high-performance diagnostics for infectious disease, cardiometabolic disease and toxicology are designed to meet the growing global demand for accurate, easy-to-use and cost-effective near-patient tests. Our goal is to make our products accessible to more people around the world, even those located in remote and resource-limited areas, by making them affordable and usable in any setting. By making critical clinical diagnostic information available to doctors and patients in an actionable timeframe, our products help streamline healthcare delivery and improve patient outcomes.

Recent Developments

Merger Agreement with Abbott Laboratories

On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a newly formed, wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, holders of shares of our common stock will receive $56.00 in cash, without interest, in exchange for each share of common stock. Each share of our Series B Convertible Perpetual Preferred Stock, par value $0.001 per share, or Series B Preferred Stock, issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. The Merger Agreement was approved by our board of directors. Completion of the merger is subject to customary closing conditions, including (1) the adoption of the Merger Agreement by the affirmative vote of the holders of at least a majority of all outstanding shares of our common stock, (2) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger and (3) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Merger Agreement. The Merger Agreement contains certain termination rights and provides that, upon termination of the Merger Agreement under certain circumstances, Alere would be required to pay Abbott a termination fee equal to $177.0 million. We are confident that the transaction will be completed in accordance with the terms set forth in the Merger Agreement.

On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act to not less than 60 days after Abbott and Alere have certified substantial compliance with the second request, unless the period is further extended voluntarily by the parties or terminated sooner by the FTC. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. Under the terms of the Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Merger Agreement, subject to certain exceptions set forth in the Merger Agreement.

In addition, after entering into the Merger Agreement, Abbott informed us that it had serious concerns about, among other things, the accuracy of various representations, warranties and covenants made by us in the Merger Agreement. Abbott indicated that these concerns relate to the delay in filing our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 as well as governmental investigations previously announced by us. Abbott has since requested information from us about these and other matters, citing contractual rights to receive information under the Merger Agreement. In the initial meeting in which Abbott expressed its concerns to us, as part of a discussion about potential paths forward, Abbott requested that we agree to terminate the Merger Agreement in return for a payment by Abbott to us in the range of between $30 and $50 million in respect of our transaction expenses. Our Board of Directors promptly rejected that request. In these discussions, Abbott affirmed its commitment to abide by its obligations under the Merger Agreement.

 

42


Table of Contents

On August 25, 2016, we filed a complaint against Abbott in Delaware Chancery Court, which seeks to compel Abbott to fulfill its obligations under the terms of the Merger Agreement to take all actions necessary to promptly obtain all required antitrust approvals for the merger. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We have asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement.

INRatio and INRatio®2 PT/INR Monitoring System Voluntary Withdrawal

In July 2016 we announced that we will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 PT/INR Monitoring System. We are currently working with the FDA on implementing the product withdrawal and eventual product discontinuation.

In December 2014, we initiated a voluntary correction to inform users of the Alere INRatio and INRatio2 PT/INR Monitoring Systems that patients with certain medical conditions should not be tested with the systems. We proactively reported these device concerns to the FDA and began conducting a thorough investigation into these events.

Over the course of the past two years, Alere invested in the research and development of software enhancements intended to address the potential, in certain cases, of the system to deliver a result that differs from that of another measurement method.

We submitted the software enhancements to the FDA at the end of 2015. The FDA notified us that it believes that our studies do not adequately demonstrate the effectiveness of the software modification and advised us to submit a proposed plan to voluntarily remove the INRatio® device from the market.

In light of this input from the FDA and our business considerations, in July 2016 we determined to voluntarily remove the INRatio systems from the market.

Due to the fact that the circumstances giving rise to the voluntary withdrawal in the United States and related action outside the U.S. existed as of December 31, 2015, certain charges incurred in connection with the withdrawal were recorded in the fourth quarter of 2015. Specifically, we recorded a charge of approximately $38 million in the year ended December 31, 2015, related to impairment of inventory and production equipment and estimated costs of removing our INRatio and INRatio2 from the market. As of June 30, 2016, $16.0 million of the estimated costs of removing INRatio and INRatio 2 from the market were included in accrued expenses. Additionally, our decision to withdraw the INRatio and INRatio2 PT/INR Monitoring Systems impacted the useful life assumptions of certain tangible and intangible assets. As a result of this change in estimate, we recorded approximately $4.1 million and $8.2 million of accelerated amortization of intangible assets and approximately $0.8 million and $1.5 million of accelerated depreciation of tangible assets in the three and six months ended June 30, 2016, respectively. Finally, during the remainder of fiscal year 2016 we expect to incur approximately $8.2 million of accelerated amortization, approximately $1.6 million of accelerated depreciation, and $2.0 million of other one-time cash expenditures.

Alere Home Monitoring, our patient self-testing anticoagulation business, will continue to distribute other PT/INR coagulation monitors following the withdrawal of the INRatio and INRatio2 PT/INR Monitoring Systems from the market.

Amendments to our Credit Agreement

On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement pursuant to which they agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for the year ended December 31, 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of certain financial statements as a result of our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the audit of our financial statements for the year ended December 31, 2015, to the extent that such breach is due to our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for the year ended December 31, 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we were required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016. We made the required deliveries before that date. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.250% of the sum of (i) the aggregate principal amount of such lender’s Term Loans (as defined in the Credit Agreement) outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $4.5 million in the aggregate for all consenting lenders. The amendment also increased the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility.

On August 18, 2016, we and the requisite lenders under the Credit Agreement entered into a further amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) (x) the financial statements and certain related deliverables for the three months ended March 31, 2016,

 

43


Table of Contents

which we refer to as the Q1 Financial Reports, by the applicable deadline under the Credit Agreement or (y) the financial statements and certain related deliverables for the three months ended June 30, 2016, which we refer to as the Q2 Financial Reports, by the applicable deadline under the Credit Agreement, and (ii) extend the deadline for delivery of the Q1 Financial Reports to August 25, 2016 and the deadline for the delivery of the Q2 Financial Reports to September 13, 2016. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.125% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment outstanding on the effective date of the amendment, or approximately $2.2 million in the aggregate for all consenting lenders.

Consent Solicitation to Note Holders

On April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and our subsequent Quarterly Reports on Form 10-Q, or the Failures to File. In connection with the Failures to File, we paid, in May and July 2016, to each holder of Notes who validly delivered a consent aggregate cash payments equal to $15.00 for each $1,000 aggregate principal amount of such holder’s Notes, or an aggregate of $19.2 million.

Financial Highlights

 

    Net revenue decreased by $12.3 million, or 2%, to $611.1 million for the three months ended June 30, 2016 from $623.4 million for the three months ended June 30, 2015. Net revenue decreased by $47.0 million, or 4%, to $1.19 billion for the six months ended June 30, 2016 from $1.24 billion for the six months ended June 30, 2015.

 

    Gross profit decreased by $5.5 million, or 2%, to $281.9 million for the three months ended June 30, 2016 from $287.3 million for the three months ended June 30, 2015. Gross profit decreased by $34.4 million, or 6%, to $548.1 million for the six months ended June 30, 2016 from $582.5 million for the six months ended June 30, 2015.

 

    For the three months ended June 30, 2016, we generated net loss available to common stockholders of $40.3 million, or $0.46 per basic and diluted common share, compared to net income available to common stockholders of $9.1 million, or $0.11 per basic and diluted common share, for the three months ended June 30, 2015. For the six months ended June 30, 2016, we generated a net loss available to common stockholders of $55.7 million, or $0.64 per basic and diluted common share, compared to net income available to common stockholders of $214.2 million, or $2.53 per basic and diluted common share, for the six months ended June 30, 2015. The net income generated in the six months ended June 30, 2015 was largely attributable to a $363.3 million pre-tax gain ($216.8 million, net of tax) on the sale of our health management business.

 

    For the three months ended June 30, 2016, loss from continuing operations available to common stockholders was $40.3 million, or $0.46 per basic and diluted common share, compared to an income from continuing operations available to common stockholders of $9.1 million, or $0.11 per basic and diluted common share, for the three months ended June 30, 2015. For the six months ended June 30, 2016, the loss from continuing operations available to common stockholders was $55.7 million, or $0.64 per basic and diluted common share, compared to a loss from continuing operations available to common stockholders of $2.6 million, or $0.03 per basic and diluted common share, for the six months ended June 30, 2015.

Results of Operations

The following discussion relates primarily to our results of operations from our continuing operations, as reflected in our accompanying consolidated statements of operations.

In connection with the preparation of our consolidated financial statements for 2015, we determined that, in 2013 and 2014, each of the interim periods in 2014, and the first three quarters of fiscal 2015, we had incorrectly reported the revenue for such periods. In addition, we made several out-of-period adjustments related to the first and second quarters of 2015. As a result, we have revised our consolidated financial information for the three and six months ended June 30, 2015, and the financial information presented below in this Item 2 reflects these revisions. For more information on these revisions, see Note 2 to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Further, of the revenue that we deferred in connection with the revision of our financial statements through September 30, 2015, approximately $9.0 million and $1.0 million remained deferred at December 31, 2015 and June 30, 2016, respectively. Where discussed, results excluding the impact of foreign currency translation are calculated on the basis of local currency results, using foreign currency exchange rates applicable to the earlier comparative period. We believe presenting information using the same foreign currency exchange rates helps investors isolate the impact of changes in those rates from other factors.

 

44


Table of Contents

Net Product Sales and Services Revenue, Total and by Business Segment. Total net product sales and services revenue decreased by $9.1 million, or 1%, to $608.6 million for the three months ended June 30, 2016, from $617.7 million for the three months ended June 30, 2015. Net product sales and services revenue decreased during the three months ended June 30, 2016 when compared to the same period in the prior year primarily as a result of a $16.4 million reduction in revenue due to the disposition of our BBI business in November 2015, a $10.5 million decrease in revenue from our mail order diabetic supplies business, and a $10.1 million unfavorable impact of foreign currency exchange rates. These revenue declines were partially offset by sales increases during the three months ended June 30, 2016 of $17.3 million in our infectious disease business and $4.2 million increase in revenues from Alere Home Monitoring, our patient self-testing anticoagulation business. The revenue decline was also partially offset by revenues of $5.5 million attributable to our acquisition of US Diagnostics in July 2015.

Total net product sales and services revenue decreased by $41.8 million, or 3%, to $1.18 billion for the six months ended June 30, 2016, from $1.23 billion for the six months ended June 30, 2015. Net product sales and services revenue decreased during the six months ended June 30, 2016 when compared to the same period in the prior year primarily as a result of a $30.7 million reduction in revenue attributable to the disposition of our BBI business in November 2015, a $26.2 million unfavorable impact of foreign currency exchange rates, a $10.7 million reduction in toxicology pain management sales, and a $10.3 million decrease revenues from in our mail order diabetic supplies business. The revenue declines were partially offset by sales increases of $15.2 million from our infectious disease business and a $7.4 million increase from sales by Alere Home Monitoring, our patient self-testing anticoagulation business. The revenue decline was also partially offset by revenues of $11.1 million attributable to our acquisition of US Diagnostics in July 2015.

Net product sales and services revenue by business segment for the three and six months ended June 30, 2016 and 2015 are as follows (in thousands):

 

     Three Months Ended June 30,      %
Change
    Six Months Ended June 30,      %
Change
 
     2016      2015        2016      2015     

Professional diagnostics

   $ 588,761       $ 593,032         (1 )%    $ 1,146,799       $ 1,179,259         (3 )% 

Consumer diagnostics

     19,794         24,645         (20 )%      37,236         46,612         (20 )% 
  

 

 

    

 

 

      

 

 

    

 

 

    

Net product sales and services revenue

   $ 608,555       $ 617,677         (1 )%    $ 1,184,035       $ 1,225,871         (3 )% 
  

 

 

    

 

 

      

 

 

    

 

 

    

Professional Diagnostics

The following table summarizes our net product sales and services revenue from our professional diagnostics business segment by groups of similar products and services for the three and six months ended June 30, 2016 and 2015 (in thousands):

 

     Three Months Ended June 30,      %
Change
    Six Months Ended June 30,      %
Change
 
     2016      2015        2016      2015     

Cardiometabolic

   $ 203,982       $ 211,672         (4 )%    $ 398,559       $ 412,608         (3 )% 

Infectious disease

     190,168         172,834         10     373,402         358,236         4

Toxicology

     158,199         157,495         —       304,982         306,251         —  

Other

     36,412         51,031         (29 )%      69,856         102,164         (32 )% 
  

 

 

    

 

 

      

 

 

    

 

 

    

Professional diagnostics net product sales and services revenue

   $ 588,761       $ 593,032         (1 )%    $ 1,146,799       $ 1,179,259         (3 )% 
  

 

 

    

 

 

      

 

 

    

 

 

    

Net product sales and services revenue from our professional diagnostics business segment decreased by $4.3 million, or 1%, to $588.8 million for the three months ended June 30, 2016, from $593.0 million for the three months ended June 30, 2015 driven primarily by the negative impact of foreign currency exchange rates and divested businesses. This negative impact was offset in part by the growth of sales in international markets.

Net product sales and services revenue from our professional diagnostics business segment decreased by $32.5 million, or 3%, to $1.15 billion for the six months ended June 30, 2016, from $1.18 billion for the six months ended June 30, 2015 primarily as a result of decreased revenues in international markets, lower pain management sales, and lower revenue in our mail order diabetic supplies business, partially offset by increased revenues due to our acquisition of US Diagnostics.

Net product sales and services revenue from our professional diagnostics business segment in the U.S. decreased by $7.0 million, or 2%, to $315.3 million for the three months ended June 30, 2016 from $322.3 million for the three months ended June 30, 2015. The decrease during the three months ended June 30, 2016 when compared to the same period in the prior year is primarily driven by a $10.5 million decline in our mail order diabetic supplies revenue, and a $4.7 million decline due to the disposition of our BBI business. The revenue declines were partially offset by $5.2 million of revenue due to our acquisition of US Diagnostics and increased revenues of $4.2 million from our Alere Home Monitoring business.

 

45


Table of Contents

Net product sales and services revenue from our professional diagnostics business segment in the U.S. decreased by $8.0 million, or 1%, to $633.2 million for the six months ended June 30, 2016 from $641.2 million for the six months ended June 30, 2015. The decrease during the six months ended June 30, 2016 when compared to the same period in the prior year was primarily driven by revenue declines of $10.7 million in our US toxicology pain management business and $10.3 million in our mail order diabetic supplies business. U.S. revenues also declined by $8.9 million due to the disposition of our BBI business. These revenue declines were partially offset by $10.6 million in revenues attributable to our acquisition of US Diagnostics and increased revenues of $7.4 million due to our Alere Home Monitoring business.

In international markets, net product sales and services revenue from our professional diagnostics business segment increased $2.7 million, or 1%, to $273.5 million during the three months ended June 30, 2016, from $270.8 million in the comparable period in 2015. The higher sales in international markets during the three months ended June 30, 2016 when compared to the same period in the prior year were driven by a $7.4 million, or 9%, increase in revenues attributable to the Asia Pacific region predominately due to infectious disease products. This increase in international revenues was partially offset by a $5.6 million decrease in European sales, primarily due to the disposition of the BBI business in November 2015 and the impact of foreign currency exchange rates, as well as the impact of foreign currency exchange rates in other regions in which we operate.

Net product sales and services revenue from our professional diagnostics business segment in international markets decreased $24.4 million, or 5%, to $513.6 million during the six months ended June 30, 2016, from $538.0 million in the comparable period in 2015. The lower sales in international markets were driven primarily by a $21.5 million, or 10%, decrease in revenues attributable to Europe, primarily due to the disposition of the BBI business in November 2015 and the impact of foreign currency exchange rates.

Within our professional diagnostics business segment, our cardiometabolic net product sales and services revenue decreased by $7.7 million, or 4%, to $204.0 million for the three months ended June 30, 2016, from $211.7 million in the same period in 2015, primarily as a result of a decline in sales by Arriva, our mail order diabetic supplies business, partially offset by increased sales by Alere Home Monitoring, our patient self-testing anticoagulation business. Infectious disease net product sales and services revenue increased by $17.3 million, or 10%, to $190.2 million for the three months ended June 30, 2016, from $172.8 million for the three months ended June 30, 2015. The increase in infectious disease revenue in the three months ended June 30, 2016 was primarily due to a $4.2 million increase in sales of Alere i, as well as increased sales of HIV and flu-related products in the second quarter of 2016 as compared to the second quarter of 2015. Toxicology net product sales and services revenue increased by $0.7 million, or less than 1%, to $158.2 million for the three months ended June 30, 2016, from $157.5 million for the comparable period in 2015, primarily as a result of $5.3 million of revenues due to the acquisition of US Diagnostics in July 2015, largely offset by lower pain management revenues. Other revenue decreased by $14.6 million, or 29%, to $36.4 million during the three months ended June 30, 2016, compared to $51.0 million during the comparable period in 2015, primarily due to the disposition of our BBI business.

Within our professional diagnostics business segment, our cardiometabolic net product sales and services revenue decreased by $14.0 million, or 3%, to $398.6 million for the six months ended June 30, 2016, from $412.6 million in the same period in 2015, primarily as a result of a decline in sales by Arriva and reduced revenues from sales of our Triage and cholesterol products, partially offset by increased sales by Alere Home Monitoring. Infectious disease net product sales and services revenue increased by $15.2 million, or 4%, to $373.4 million for the six months ended June 30, 2016, from $358.2 million for the six months ended June 30, 2015. The increase in infectious disease revenue in the six months ended June 30, 2016 was primarily attributable to increased revenue of $14.9 million from sales of our Alere i product, as well as increased HIV-related product sales, partially offset by the impact of foreign currency exchange rates. Toxicology net product sales and services revenue decreased by $1.3 million, or less than 1%, to $305.0 million for the six months ended June 30, 2016, from $306.3 million for the comparable period in 2015, primarily as a result of lower pain management revenues and the impact of foreign currency exchange rates in first half of 2016, partially offset by an increase of $11.1 million due to the acquisition of US Diagnostics. Other revenue decreased by $32.3 million, or 32%, to $69.9 million during the six months ended June 30, 2016, compared to $102.2 million during the comparable period in 2015, primarily due to the disposition of our BBI business.

Consumer Diagnostics

Net product sales and services revenue from our consumer diagnostics business segment decreased by $4.9 million, or 20%, to $19.8 million for the three months ended June 30, 2016, from $24.6 million for the three months ended June 30, 2015. Net product sales and services revenue from our consumer diagnostics business segment decreased by $9.4 million, or 20%, to $37.2 million for the six months ended June 30, 2016, from $46.6 million for the six months ended June 30, 2015. The decrease resulted from a $2.4 million and $4.0 million decrease in revenue attributable to the disposition of our BBI business for the three month and six months ended June 30, 2016, respectively, as compared to the three and six months ended June 30, 2015. The balance of the decrease in both the three and six months ended June 30, 2016 was the result of a decrease in sales to SPD under our long-term manufacturing service agreement.

 

46


Table of Contents

License and Royalty Revenue. License and royalty revenue represents license and royalty fees from intellectual property license agreements with third parties. License and royalty revenue decreased by $3.2 million, or 56%, to $2.5 million for the three months ended June 30, 2016 from $5.7 million for the three months ended June 30, 2015. The decrease in royalty revenue for the three months ended June 30, 2016, compared to the comparable period in 2015, is primarily a result of lower royalties earned under existing licensing agreements, as certain patents related to our lateral flow technology expired in 2015. Based on our license and royalty agreements in effect as of June 30, 2016, we expect this trend in lower license and royalty revenues to continue in 2016 as compared to 2015.

License and royalty revenue decreased by $5.1 million, or 49%, to $5.3 million for the six months ended June 30, 2016 from $10.4 million for the six months ended June 30, 2015. The decrease in royalty revenue for the six months ended June 30, 2016, compared to the comparable period in 2015, is primarily a result of lower royalties earned under existing licensing agreements, as certain patents related to our lateral flow technology expired in 2015.

Gross Profit and Margin Percentage. Gross profit decreased by $5.5 million, or 2%, to $281.9 million for the three months ended June 30, 2016 from $287.3 million for the three months ended June 30, 2015. The decrease in gross profit during the three months ended June 30, 2016, compared to the same period in 2015, was largely attributed to a $9.3 million decrease in gross profit as a result of our divested businesses and a $4.7 million negative impact of foreign currency exchange rates, offset partially by the $2.7 million increase from our acquired businesses, as well as the improved gross profit of our Alere Home Monitoring business and growth in sales in the Asia–Pacific region, largely due to our infectious disease business, as discussed above.

Gross profit decreased by $34.4 million, or 6%, to $548.1 million for the six months ended June 30, 2016 from $582.5 million for the six months ended June 30, 2015. The decrease in gross profit during the six months ended June 30, 2016, compared to the comparable period in 2015, was largely attributed to $15.9 million decrease in gross profit due to our divested businesses, a $11.0 million negative impact of foreign currency exchange rates, as well as the impact from lower revenues discussed above and decreased manufacturing volumes.

Overall gross margin for each of the three and six months ended June 30, 2016 was 46%, as compared to 46% and 47%, respectively, for the three and six months ended June 30, 2015.

Gross Profit from Net Product Sales and Services Revenue, Total and by Business Segment. Gross profit from net product sales and services revenue decreased by $3.1 million, or 1%, to $279.9 million for the three months ended June 30, 2016 from $283.0 million for the three months ended June 30, 2015. Gross profit from net product sales and services revenue decreased by $30.7 million, or 5%, to $544.8 million for the six months ended June 30, 2016 from $575.5 million for the six months ended June 30, 2015. Gross profit from net product sales and services revenue by business segment for the three and six months ended June 30, 2016 and 2015 is as follows (in thousands):

 

     Three Months Ended June 30,      %
Change
    Six Months Ended June 30,      %
Change
 
     2016      2015        2016      2015     

Professional diagnostics

   $ 278,684       $ 281,501         (1 )%    $ 542,652       $ 570,810         (5 )% 

Consumer diagnostics

     1,178         1,483         (21 )%      2,130         4,641         (54 )% 
  

 

 

    

 

 

      

 

 

    

 

 

    

Gross profit from net product sales and services revenue

   $ 279,862       $ 282,984         (1 )%    $ 544,782       $ 575,451         (5 )% 
  

 

 

    

 

 

      

 

 

    

 

 

    

Professional Diagnostics

Gross profit from our professional diagnostics net product sales and services revenue decreased by $2.8 million, or 1%, to $278.7 million for the three months ended June 30, 2016 compared to $281.5 million for the three months ended June 30, 2015. The lower gross profit for the three months ended June 30, 2016 as compared to the same period in the prior year principally reflects the $9.4 million decreases in gross profit as a result of divested businesses and $4.6 million due to the negative impact of foreign currency exchange rates, partially offset by a $2.7 million increase in gross profit from acquired businesses, as well as improved gross profit from our Alere Home Monitoring business and growth in sales in the Asia Pacific region, largely due to our infectious disease business, as discussed above.

Gross profit from our professional diagnostics net product sales and services revenue decreased by $28.2 million, or 5%, to $542.7 million for the six months ended June 30, 2016 compared to $570.8 million for the six months ended June 30, 2015. The lower gross profit for the six months ended June 30, 2016 as compared to the same period in the prior year principally reflects the $16.1 million impact from divested businesses and $10.9 million due to the negative impact of foreign currency exchange rates as well as the impact from lower revenues discussed above and decreased manufacturing volumes. These decreases to gross profit were partially offset by a $5.0 million increase in gross profit from our acquired businesses.

 

47


Table of Contents

As a percentage of our professional diagnostics net product sales and services revenue, gross margin for the three and six months ended June 30, 2016 was 47%, compared to 47% and 49% for the three and six months ended June 30, 2015, respectively. The lower gross margin in the six months ended June 30, 2016 principally reflects the impact of decreased manufacturing volumes and the revenue mix as discussed above.

Consumer Diagnostics

Gross profit from our consumer diagnostics net product sales and services revenue decreased by $0.3 million, or 21%, to $1.2 million for the three months ended June 30, 2016 from $1.5 million for the three months ended June 30, 2015.

Gross profit from our consumer diagnostics net product sales and services revenue decreased by $2.5 million, or 54%, to $2.1 million for the six months ended June 30, 2016 from $4.6 million for the six months ended June 30, 2015. The decrease in gross profit was primarily driven by decreased sales to SPD, as described above.

As a percentage of our consumer diagnostics net product sales and services revenue, gross margin for the three and six months ended June 30, 2016 was 6%, compared to 6% and 10% for the three and six months ended June 30, 2015, respectively.

Research and Development Expense. Research and development expense increased by $1.2 million, or 5%, to $28.4 million in the three months ended June 30, 2016 from $27.2 million in the three months ended June 30, 2015, primarily due to restructuring expenses. Research and development expense during the three months ended June 30, 2016 and 2015 is reported net of grant funding of $0.3 million and $1.5 million, respectively, arising from the research and development funding relationship with the Bill and Melinda Gates Foundation, or the Gates Foundation, and $1.0 million and $0.9 million of funding, respectively, related to our contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, that we entered into in September 2014. For additional information on the agreements with BARDA and the Gates Foundation, including the April 2016 agreement to mutually terminate the February 2013 grant and the February 2013 loan agreement with the Gates Foundation, see Note 16 to the consolidated financial statements elsewhere in this Quarterly Report on Form 10-Q.

Research and development expense increased by $0.3 million, or 1%, to $55.5 million in the six months ended June 30, 2016 from $55.2 million in the six months ended June 30, 2015, primarily from restructuring expenses and partially offset by the favorable impact of foreign exchange rates. Research and development expense during the six months ended June 30, 2016 and 2015 is reported net of grant funding of $0.5 million and $3.6 million, respectively, arising from the research and development funding relationship with the Gates Foundation, and $1.7 million and $1.4 million, respectively, of funding related to our contract with BARDA.

Research and development expense as a percentage of net revenue was 5% and 4% for the three and six months ended June 30, 2016 and 2015, respectively.

Sales and Marketing Expense. Sales and marketing expense decreased by $5.5 million, or 5%, to $102.5 million for the three months ended June 30, 2016 from $108.0 million for the three months ended June 30, 2015. This decrease was primarily attributable to a $2.2 million reduction in sales and marketing expenses associated with businesses we divested after March 31, 2015, a $1.7 million reduction in amortization expense related to customer relationship intangible assets (as the underlying economic benefit of the intangibles is declining) and a $1.2 million favorable impact of foreign currency exchange rates.

Sales and marketing expense decreased by $14.8 million, or 7%, to $202.3 million for the six months ended June 30, 2016 from $217.1 million for the six months ended June 30, 2015. This decrease was primarily attributable to a $5.0 million reduction in sales and marketing expenses associated with businesses we divested after March 31, 2015, a $4.0 million favorable impact of foreign currency exchange rates, a $3.0 million reduction in amortization expense related to customer relationship intangible assets and a $1.0 million decrease in restructuring expenses.

Sales and marketing expense as a percentage of net revenue was 17% for each of the three and six months ended June 30, 2016, compared to 17% and 18% for the three and six months ended June 30, 2015, respectively.

General and Administrative Expense. General and administrative expense increase by $67.2 million, or 110%, to $128.4 million for the three months ended June 30, 2016 from $61.2 million for the three months ended June 30, 2015. The increase was primarily attributable to the fact that, in the three months ended June 30, 2015, we benefited from a $41.1 million gain resulting from a decrease in our estimate of the fair value of an acquisition-related contingent earn-out obligation. In the three months ended June 30, 2016, we also incurred $10.5 million of expenses related to the pending transaction with Abbott. The remaining portion of the increase, or an aggregate of $15.6 million, is primarily attributable to $11.5 million increase in various employee related expenses, $5.0 million in legal and consulting fees related to certain government investigations and $3.6 million in charges associated with our various restructuring plans to reduce expenses. These expenses were partially offset by decreased expenses as a result of divestitures and disposal fees of businesses, foreign currency exchange rates and the reduced expense due to the delay in the medical device excise tax, in each case when compared to the comparable period in 2015.

 

48


Table of Contents

General and administrative expense increased by $89.4 million, or 58%, to $243.3 million for the six months ended June 30, 2016 from $153.9 million for the six months ended June 30, 2015. The increase was primarily attributable to the fact that, in the six months ended June 30, 2015, we benefited from a $52.9 million gain resulting from decreases in our estimate of the fair value of an acquisition-related contingent earn-out obligation. In the six months ended June 30, 2016, we also incurred $20.9 million of expenses related to the pending transaction with Abbott. The remaining portion of the increase, or an aggregate of $15.6 million, is attributable to $9.4 million in legal and consulting fees related to certain government investigations, $6.6 million in charges associated with our various restructuring plans to reduce expenses. We also incurred a $17.4 million increase in various employee related expenses which were completely offset by decreased expenses as a result of divestitures and disposal fees of businesses, favorable foreign currency exchange rates and the reduced expense due to delay in the medical device excise tax, in each case when compared to the comparable period in 2015.

General and administrative expense as a percentage of net revenue was 21% and 20% for the three and six months ended June 30, 2016, respectively, compared to 10% and 12% for the three and six months ended June 30, 2015. This increase was largely due to the gain from an acquisition-related contingent earn-out obligation in the three months ended June 30, 2015 for which there was no corresponding gain in the three months ended June 30, 2016.

Impairment and (Gain) Loss on Dispositions, Net. In January 2016, we completed the sale of our Alere E-Santé business,

which was a component of our professional diagnostics reporting unit and business segment. We received cash consideration of approximately $8.1 million, net of a final working capital adjustment totaling approximately $0.2 million, and we are eligible to receive up to $1.5 million of contingent cash consideration. As a result of this transaction, we recorded a $3.8 million gain in the three months ended March 31, 2016 on the disposition of the Alere E-Santé business.    

In May 2015, we sold our Alere Analytics business, which was part of our professional diagnostics reporting unit and business segment. Under the terms of the sale we received nominal consideration and agreed to contribute working capital of $2.7 million to Alere Analytics, of which $2.4 million was contributed in cash immediately prior to the closing of the sale and the remaining $0.3 million of which was deposited in escrow pending the performance by the buyers under certain contracts. As a result of this transaction we recorded a loss of $4.7 million during the second quarter of 2015. During the three months ended March 31, 2015, before identifying a buyer for Alere Analytics, our management decided to close the business, and in connection with this decision we recorded an impairment charge of $26.7 million during that quarter, including the write-off of $26.2 million of acquisition-related intangible assets and $0.5 million of fixed assets.

In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during the three months ended March 31, 2015.

In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for €7.6 million (approximately $8.2 million at March 31, 2015) and, as a result of this transaction, we recorded a loss on disposition of $7.5 million during the three months ended March 31, 2015.

In December 2014, our management decided to close our Alere Connect, LLC subsidiary, which is part of our professional diagnostics reporting unit and business segment. During the six months ended June 30, 2015, in connection with this decision, we recorded impairment charges of $1.0 million, consisting primarily of severance costs, inventory write-offs and other closure-related expenses.

The financial results for the above businesses are immaterial to our consolidated financial results.

Interest Expense. Interest expense includes interest charges and the amortization of deferred financing costs and original issue discounts associated with certain debt issuances. Interest expense decreased by $17.2 million, or 29%, to $42.3 million for the three months ended June 30, 2016 from $59.5 million for the three months ended June 30, 2015. The decrease was driven by $10.2 million of third-party costs, including underwriter’s fees and other payments to external advisors, that we incurred in the three months ended June 30, 2015 associated with the credit facility that we put in place in that quarter. The decrease was also due to lower interest expense incurred as a result of our reduced outstanding debt balances during the second quarter of 2016.

Interest expense decreased by $21.5 million, or 20%, to $84.4 million for the six months ended June 30, 2016 from $105.9 million for the six months ended June 30, 2015. The decrease is due to lower interest expense incurred as a result of our reduced outstanding debt balances during the six months ended June 30, 2016. The decrease was also driven by $10.2 million of third-party costs that we incurred in the second quarter of 2015, as noted above.

 

49


Table of Contents

Other Income (Expense), Net. Other income (expense), net includes interest income, realized and unrealized foreign exchange losses, and other income (expense), net. The components and the respective amounts of other income (expense), net are summarized as follows (in thousands):

 

     Three Months Ended June 30,           Six Months Ended June 30,        
     2016     2015     Change     2016     2015     Change  

Interest income

   $ 645      $ 728      $ (83   $ 1,810      $ 1,327      $ 483   

Foreign exchange gains (losses), net

     (5,705     2,906        (8,611     (7,907     (696     (7,211

Other, net

     (9,052     (439     (8,613     (9,364     197        (9,561
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense), net

   $ (14,112   $ 3,195      $ (17,307   $ (15,461   $ 828      $ (16,289
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Interest income is related principally to our cash deposits, including restricted cash.

Foreign exchange gains (losses), net during the three and six months ended June 30, 2016 were primarily related to the impact of foreign currency translation on intercompany balances denominated in British Pound Sterling and Korean Won.

Other, net for the three and six months ended June 30, 2016 primarily reflects a $10.2 million accrual in connection with an on-going governmental investigation that commenced in May 2012 when we received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG. For additional information on this matter, see Part II — Item 1. Legal Proceedings Matters Relating to our San Diego Facility included elsewhere in this Quarterly Report on Form 10-Q.

Provision for Income Taxes. Our provision for income taxes decreased by $12.6 million to $3.1 million for the three months ended June 30, 2016, from $15.7 million for the three months ended June 30, 2015. The effective tax rate for the three months ended June 30, 2016 and 2015 was (9)% and 54%, respectively. Our effective tax rate is primarily impacted by changes in the forecasted income (loss) across various jurisdictions as well as items that are accounted for discretely in the quarter. The decrease in the provision for income taxes from the three months ended June 30, 2015 to the three months ended June 30, 2016 is primarily attributed to favorable jurisdictional mix of income and losses in the current year and non-recurring discrete tax impacts in 2015.

Our provision for income taxes decreased by $5.0 million to $2.9 million for six months ended June 30, 2016 from $7.9 million for the six months ended June 30, 2015. The effective tax rate for the six months ended June 30, 2016 and 2015 was (6)% and 72%, respectively. The decrease in our provision for income taxes for six months ended June 30, 2016 compared to six months ended June 30, 2015 is primarily attributed to favorable jurisdictional mix of income and losses in the current year and non-recurring discrete tax impacts in 2015.

Equity Earnings of Unconsolidated Entities, Net of Tax. Equity earnings of unconsolidated entities are reported net of tax and include our share of earnings in entities that we account for under the equity method of accounting. Equity earnings of unconsolidated entities, net of tax for the three and six months ended June 30, 2016 reflects the following: (i) our 50% interest in SPD in the amount of $1.6 million and $6.2 million, respectively, and (ii) our 49% interest in TechLab, Inc., or TechLab, in the amount of $0.6 million and $1.0 million, respectively. Equity earnings of unconsolidated entities, net of tax for the three and six months ended June 30, 2015 reflects the following: (i) our 50% interest in SPD in the amount of $0.6 million and $4.2 million, respectively, (ii) our 49% interest in TechLab in the amount of $0.4 million and $0.8 million, respectively.

Income from Discontinued Operations, Net of Tax. The results of our former health management business are included in income from discontinued operations, net of tax, for the six months ended June 30, 2015, given our January 9, 2015 divestiture of this business. For the six months ended June 30, 2015, the discontinued operations generated income, net of tax, of $216.8 million. This income from discontinued operations was largely attributable to a $366.2 million pre-tax gain ($218.6 million, net of tax) on the sale of our health management business. See Note 4 of our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Liquidity and Capital Resources

Based upon our current working capital position, current operating plans and expected business conditions, we expect to fund our short and long-term working capital needs primarily using existing cash and our operating cash flow. As of June 30, 2016, we had approximately $3.0 billion of indebtedness outstanding. As our various debt instruments mature over the next several years, we may

 

50


Table of Contents

need or want to re-finance some or all this indebtedness with new debt, including potential borrowings under our revolving credit facility, in order to preserve our existing cash for other uses, including to continue to fund our operations. During the six months ended June 30, 2016, we generated net cash proceeds of $21.5 million from divestitures, net of cash divested, and used $17.4 million of our cash to reduce our outstanding indebtedness under our credit facilities. In May 2016, we paid approximately $152.0 million in cash to satisfy the principal and interest due under our 3% convertible senior subordinated notes, which matured on May 15, 2016 (of which amount $125.0 million was drawn under our revolving credit facility and $27.0 million was paid using available cash). We may divest one or more of our businesses in accordance with the covenants under the Merger Agreement with Abbott and we expect that, if and when completed, we will use all or a portion of the net proceeds of such divestitures to fund our working capital, operations, research and development or to reduce our outstanding debt, among other purposes, in each case to the extent permitted under the Merger Agreement and in accordance with our secured credit facility and the indentures governing our notes. As of June 30, 2016, we had $506.2 million of cash and cash equivalents, of which $60.2 million was held by domestic subsidiaries and $446.0 million was held by foreign entities. We do not currently plan to repatriate cash held by most of our foreign entities if there are adverse tax implications, including incremental U.S. tax liabilities and potential foreign withholding tax liabilities. If circumstances were to change, however, we may be required to repatriate all or a portion of the cash held by foreign entities, which could result in the payment of significant tax liabilities.

We may also utilize amounts available under our secured credit facility, as described below, or other new sources of financing to fund a portion of our capital expenditures, contractual contingent consideration obligations, other commitments, the refinancing of existing indebtedness and future acquisitions. New sources of financing may not be available on acceptable terms, or at all, and we may be required to obtain certain consents in connection with completing such financings, which we may not be able to obtain on acceptable terms or at all.

On June 18, 2015, we entered into a new secured credit facility, which initially provided for term loan facilities totaling $1.7 billion (consisting of $650 million of “A” term loans and $1.05 billion of “B” term loans), all of which were drawn at closing, and, subject to our continued compliance with the secured credit facility, a $250.0 million revolving credit facility (which includes a $50.0 million sublimit for the issuance of letters of credit). As of June 30, 2016, $125.0 million was drawn and outstanding under the revolving credit facility.

We used approximately $1.68 billion of the proceeds of the term loans drawn at closing to repay in full all indebtedness outstanding under our prior credit facility, whereupon that facility was terminated, and to pay various fees and expenses associated with the transactions contemplated by the new secured credit facility.

In November 2015 we used $115.0 million of the net cash proceeds from our sale of the BBI business (which represented all of the net proceeds from the closing of the sale prior to giving effect to the final working capital adjustment) to repay $115.0 million in aggregate principal amount of outstanding “A” term loans and “B” term loans under the secured credit facility.

We must repay the “A” term loans in nineteen consecutive quarterly installments, which began on September 30, 2015 and continue through March 31, 2020, followed by a final installment on June 18, 2020; after giving effect to the prepayment of a portion of the “A” term loans in connection with our sale of the BBI business, the principal amount of each remaining installment through March 31, 2020 is approximately $7,572,000, and the principal amount of the final installment is approximately $461,882,000. We must repay the “B” term loans in twenty-seven consecutive quarterly installments, which began on September 30, 2015 and continue through March 31, 2022, followed by a final installment on June 18, 2022; after giving effect to the prepayment of a portion of the “B” term loans in connection with our sale of the BBI business, the principal amount of each remaining installment through March 31, 2022 is approximately $2,446,000, and the principal amount of the final installment is approximately $912,471,000. We may repay any borrowings under the revolving credit facility at any time (without any premium or penalty, other than customary LIBOR breakage costs, if applicable), but in no event later than June 18, 2020.

As of June 30, 2016, we had $3.0 billion in aggregate principal amount of outstanding indebtedness, including $1.5 billion in aggregate principal amount outstanding under our secured credit facility, $442.5 million in aggregate outstanding principal amount of our 7.25% senior notes due 2018, $415.7 million in aggregate outstanding principal amount of our 6.5% senior subordinated notes due 2020 and $414.0 million in aggregate outstanding principal amount of our 6.375% senior subordinated notes due 2023. As noted above, our 3% convertible senior subordinated notes matured on May 15, 2016, and we used $125.0 million of cash drawn under our revolving credit facility plus $27.0 million of available cash to pay the $152.0 million of outstanding principal and accrued interest due under the notes. The terms and conditions of our outstanding debt instruments contain covenants that expressly restrict our ability to incur additional indebtedness and conduct other financings, subject to certain exceptions. In addition, the Merger Agreement with Abbott contains restrictions on our ability to incur additional indebtedness and conduct other financings, subject to certain exceptions.

On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement, or the April 2016 Amendment. Pursuant to the April 2016 Amendment, these lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of

 

51


Table of Contents

certain financial statements as a result of our incorrect application of revenue recognition principles for 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the audit of our financial statements for 2015, to the extent that such breach is due to our incorrect application of revenue recognition principles for 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we were required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016. We made the required deliveries before such date. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.250% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (each as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $4.5 million in the aggregate for all consenting lenders. The amendment also increased the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility.

In addition, on April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, 6.375% senior subordinated notes and 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC, or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and our subsequent Quarterly Reports on Form 10-Q, or the Failures to File. In connection with the Failures to File, we paid, in May and July 2016, to each holder of Notes who validly delivered a consent aggregate cash payments equal to $15.00 for each $1,000 aggregate principal amount of such holder’s Notes, or an aggregate of $19.2 million.

On August 18, 2016, we and the requisite lenders under the Credit Agreement entered into a further amendment to the Credit Agreement pursuant to which they agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) (x) the financial statements and certain related deliverables for the three months ended March 31, 2016, which we refer to as the Q1 Financial Reports, by the applicable deadline under the Credit Agreement or (y) the financial statements and certain related deliverables for the three months ended June 30, 2016, which we refer to as the Q2 Financial Reports, by the applicable deadline under the Credit Agreement, and (ii) extend the deadline for delivery of the Q1 Financial Reports to August 25, 2016 and the deadline for the delivery of the Q2 Financial Reports to September 13, 2016. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.125% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (each as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $2.2 million in the aggregate for all consenting lenders.

Our indebtedness outstanding at June 30, 2016 matures at various times between 2018 and 2023. We may not have sufficient cash resources at the time of maturity of our remaining indebtedness to pay the aggregate principal and accrued interest under such indebtedness. If the capital and credit markets experience volatility or the availability of funds is limited, we may be unable to re-finance this debt on commercially reasonable terms, including because of increased costs associated with issuing debt instruments, or at all. In addition, it is possible that our ability to access the capital and credit markets could be limited by the amount of our indebtedness or other factors at a time when we would like, or need, to do so, which could have an adverse impact on our ability to refinance maturing debt and/or react to changing economic and business conditions.

Our funding plans for our working capital needs and other commitments may be adversely impacted if our underlying assumed revenues and expenses are not realized. In particular, we could experience decreased product sales or lower average selling prices, unexpected costs associated with our potential divestitures, operational integration efforts, core research and development projects, cost-saving initiatives and existing or unforeseen lawsuits, regulatory actions, governmental investigations, or other claims against us, such as those we incurred in connection with our recently announced withdrawal of our INRatio and INRatio 2 products from the market. We may also choose to make significant investment to pursue legal remedies against potential infringers of our intellectual property rights. If we decide to engage in such activities, or if our operating results fail to meet our expectations, we could be required to seek additional funding through public or private financings or other arrangements. In such event, adequate funds may not be available when needed or may be available only on terms which could have a negative impact on our business and results of operations. In addition, if we raise additional funds by issuing equity or convertible securities, dilution to then-existing stockholders may result. In connection with any such financing, we may be required to obtain consents from the requisite lenders under our secured credit facility and/or the requisite holders of our outstanding notes or from Abbott pursuant to the Merger Agreement, and there is no guarantee we will be able to obtain those consents.

 

52


Table of Contents

Cash Flow Summary (in thousands)

 

     Six Months Ended June 30,  
     2016      2015  

Net cash provided by operating activities:

     

Continuing operations

   $ 94,122       $ 34,720   

Discontinued operations

     —           318   
  

 

 

    

 

 

 

Net cash provided by operating activities

     94,122         35,038   
  

 

 

    

 

 

 

Net cash provided by (used in) investing activities:

     

Continuing operations

     (13,579      132,576   

Discontinued operations

     —           (209
  

 

 

    

 

 

 

Net cash provided by (used in) investing activities

     (13,579      132,367   
  

 

 

    

 

 

 

Net cash used in financing activities:

     

Continuing operations

     (73,615      (102,645

Discontinued operations

     —           (76
  

 

 

    

 

 

 

Net cash used in financing activities

     (73,615      (102,721
  

 

 

    

 

 

 

Foreign exchange effect on cash and cash equivalents

     (2,964      (1,574
  

 

 

    

 

 

 

Net increase in cash and cash equivalents

     3,964         63,110   

Cash and cash equivalents, beginning of period – continuing operations

     502,200         378,461   

Cash and cash equivalents, beginning of period – discontinued operations

     —           23,300   
  

 

 

    

 

 

 

Cash and cash equivalents, end of period

     506,164         464,871   

Less: Cash and cash equivalents, end of period – discontinued operations, end of period

     —          —    
  

 

 

    

 

 

 

Cash and cash equivalents of continuing operations, end of period

   $ 506,164       $ 464,871   
  

 

 

    

 

 

 

Summary of Changes in Cash Position

As of June 30, 2016, we had cash and cash equivalents of $506.2 million, a $4.0 million increase from December 31, 2015. Our primary sources of cash during the six months ended June 30, 2016 included $126.2 million related to net borrowings under revolving credit facilities, $94.1 million generated by our operating activities, $21.5 million received from dispositions, net of cash divested, $11.1 million of cash received from common stock issuances under employee stock option and stock purchase plans, $2.4 million received from equity method investments, $0.9 million in proceeds from the sale of property and equipment, $0.5 million from a decrease in other assets and $0.4 million from issuance of long-term debt. Our primary uses of cash during the six months ended June 30, 2016 were $177.6 million related to the repayment of long-term debt obligations, $32.3million of capital expenditures, $19.6 million for financing costs, $10.6 million for cash dividends paid on our Series B preferred stock, $6.0 million paid for acquisitions, $2.2 million for principal payments on our capital lease obligations, $0.8 million related to payments on short-term debt, $0.5 million related to payments of acquisition-related contingent consideration obligations and a $0.4 million related to an increase in restricted cash. Fluctuations in foreign currencies unfavorably impacted our cash balance by $3.0 million during the six months ended June 30, 2016.

As of June 30, 2015, we had cash and cash equivalents of continuing operations of $464.9 million, an $86.4 million increase from December 31, 2014. Our primary sources of cash for continuing operations during the six months ended June 30, 2015 included $2.1 billion from issuance of long-term debt, $586.6 million received from dispositions, net of cash divested, $56.3 million of cash received from common stock issuances under employee stock option and stock purchase plans, $34.7 million generated by our continuing operating activities, $14.3 million received from equity method investments, $1.8 million from a decrease in other assets, and $1.1 million in proceeds from the sale of property and equipment. Our primary uses of cash for our continuing operations during the six months ended June 30, 2015 were $2.1 billion related to the repayment of long-term debt obligations, a $424.0 million increase in restricted cash placed in a trust account for repayment of our 8.625% notes, $126.3 million related to net payments under revolving credit facilities, $47.3 million of capital expenditures, $15.7 million for financing costs, $10.6 million for cash dividends paid on our Series B preferred stock, $6.4 million related to payments of acquisition-related contingent consideration obligations and $2.9 million for principal payments on our capital lease obligations. Fluctuations in foreign currencies unfavorably impacted our cash balance by $1.6 million during the six months ended June 30, 2015.

 

53


Table of Contents

Cash Flows from Operating Activities

Net cash provided by operations during the six months ended June 30, 2016 was $94.1 million, which resulted from our loss of $44.9 million and $18.8 million of cash used to meet working capital needs during the period, offset by $157.8 million of non-cash items. The $157.8 million of non-cash items included $142.4 million related to depreciation and amortization, $20.6 million related to non-cash stock-based compensation, $9.7 million of other non-cash expenses, $5.3 million of non-cash interest expense related to the amortization of deferred financing costs and original issue discounts, a $4.2 million loss on the disposition of fixed assets, $0.9 million related to inventory impairment and $0.6 million related to fixed assets impairment, partially offset by a $13.2 million decrease related to changes in our deferred income taxes, $7.2 million in equity earnings of unconsolidated entities, net of tax, a $3.8 million gain related to impairment and net loss on dispositions and a $1.8 million non-cash change in fair value of contingent purchase price consideration, which resulted in part from amortization of intangible assets.

Net cash provided by continuing operations during the six months ended June 30, 2015 was $34.7 million, which resulted from income from continuing operations of $8.4 million and $112.1 million of non-cash items, offset by $85.8 million of cash used to meet working capital needs during the period. The $112.1 million of non-cash items included $147.1 million related to depreciation and amortization, a $40.3 million loss related to impairment and a net loss on dispositions, which reflects both a $27.7 million impairment charge associated with a closed business and a $12.6 million net loss from business dispositions, $12.3 million related to non-cash stock-based compensation, $7.8 million of non-cash interest expense related to the amortization of deferred financing costs and original issue discounts, a $3.5 million loss on the extinguishment of debt and a $3.3 million loss on the disposition of fixed assets, partially offset by a $52.9 million non-cash change in fair value of contingent purchase price consideration, a $42.2 million decrease related to changes in our deferred income taxes, which resulted in part from amortization of intangible assets, $5.3 million in equity earnings of unconsolidated entities, net of tax, and $2.3 million related to other non-cash items. In addition, $0.3 million of net cash was provided by discontinued operations for operating activities.

Cash Flows from Investing Activities

Net cash used in our investing activities during the six months ended June 30, 2016 was $13.6 million, including $32.3 million of capital expenditures, $6.0 million paid for acquisitions and $0.4 million increase in restricted cash, partially offset by $21.5 million of cash received from dispositions, net of cash divested, $2.4 million of cash received from equity method investments, $0.9 million of proceeds from the sale of property, plant and equipment and a $0.5 million decrease in other assets.

Our investing activities for continuing operations during the six months ended June 30, 2015 provided $132.6 million of cash, including, among other items, $586.6 million of cash received from the disposition of our health management business and other divestitures, net of cash divested, $14.3 million of cash received from equity method investments, a $1.8 million decrease in other assets and $1.1 million of proceeds from the sale of property, plant and equipment, partially offset by a $424.0 million increase in restricted cash, including $425.9 million placed in a trust account for repayment of long-term debt, and $47.3 million of capital expenditures. In addition, discontinued operations used $0.2 million of net cash for investing activities.

Cash Flows from Financing Activities

Net cash used in financing activities during the six months ended June 30, 2016 was $73.6 million. Financing activities during the six months ended June 30, 2016 included, among other items, $177.6 million for the payment of long-term debt obligations, $19.6 million of financing costs, $10.6 million for dividend payments related to our Series B preferred stock, $2.2 million for payment of capital lease obligations, $0.8 million for net payments for short-term debt, and $0.5 million for payments of acquisition-related contingent consideration obligations. We received $126.2 million of net proceeds from our revolving credit facilities, $11.1 million of cash from common stock issuances under our employee stock option and stock purchase plans and $0.4 million of proceeds from issuance of long-term debt.

Net cash used in financing activities for continuing operations during the six months ended June 30, 2015 was $102.6 million. Financing activities during the six months ended June 30, 2015 included, among other items, $2.1 billion for the payment of long-term debt obligations, $126.3 million for net payments for revolving credit facilities, $15.7 million for financing costs, $10.6 million for dividend payments related to our Series B preferred stock, $6.4 million for payments of acquisition-related contingent consideration obligations and $2.9 million for payment of capital lease obligations. We received $2.1 billion of proceeds from issuance of long-term debt and $56.3 million of cash from common stock issuances under employee stock option and stock purchase plans. In addition, discontinued operations used less than $0.1 million of net cash for financing activities.

As of June 30, 2016, we had an aggregate of $10.5 million in outstanding capital lease obligations which are payable through 2020.

Income Taxes

As of June 30, 2016, our federal, state and foreign net operating loss carryforwards for income tax purposes were approximately $30.6 million, $876.5 million, and $234.6 million, respectively. If not utilized, a portion of the federal, state and foreign net operating loss carryforwards will begin to expire in 2020, 2017 and 2017, respectively. Certain foreign net operating loss carryforwards can be carried forward indefinitely. As of June 30, 2016, our federal and foreign capital loss carryforwards for income tax purposes were

 

54


Table of Contents

approximately $256.1 million and $62.1 million, respectively. If not utilized, a portion of the federal capital loss carryforwards will begin to expire in 2016. The foreign capital loss carryforwards can be carried forward indefinitely. As of June 30, 2016, we had $22.9 million of U.S. federal and state research and development credit carryforwards, $4.4 million of U.S. federal Alternative Minimum Tax (“AMT”) credit carryforwards, $79.2 million of U.S. foreign tax credit carryforwards and $1.2 million of other foreign tax credit carryforwards. If not utilized, a portion of the research and development credit and foreign tax credit will begin to expire in 2026 and 2018, respectively.

We have recorded a valuation allowance against a portion of the deferred tax assets related to our U.S. foreign tax credits and certain other net operating losses, capital loss and credit carryforwards, as well as certain of our other deferred tax assets to reflect uncertainties that might affect the realization of such deferred tax assets.

Off-Balance Sheet Arrangements

We had no material off-balance sheet arrangements as of June 30, 2016.

Contractual Obligations

As of June 30, 2016, our contractual obligations have not changed significantly since December 31, 2015, as presented in our Annual Report on Form 10-K for the year ended December 31, 2015.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements in accordance with generally accepted accounting principles requires us to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a quarterly basis, we evaluate our estimates, including those related to revenue recognition and related allowances, bad debt, inventory, valuation of long-lived assets, including intangible assets and goodwill, income taxes, including any valuation allowance for our net deferred tax assets, contingent consideration obligations, contingencies and litigation, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

There were no significant changes in our critical accounting policies or management estimates between December 31, 2015 and June 30, 2016. A comprehensive discussion of our critical accounting policies and management estimates is included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2015.

Recent Accounting Pronouncements

See Note 18 of the consolidated financial statements included in this Quarterly Report on Form 10-Q, regarding the impact of certain recent accounting pronouncements on our consolidated financial statements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our market risks, and the ways we manage them, are summarized in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the year ended December 31, 2015. In the six months ended June 30, 2016, there were no material changes to our market risks or our management of such risks.

 

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), which are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our CEO and CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our CEO and CFO concluded that, as a result of the material weaknesses in internal control over financial reporting previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and described below, our disclosure controls and procedures were not effective as of June 30, 2016.

 

55


Table of Contents

Previously Reported Material Weaknesses

As reported in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2015, our management concluded that our internal control over financial reporting was ineffective as of that date because material weaknesses existed in our internal control over financial reporting related to our accounting for income taxes and revenue recognition. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Material Weakness Related to Accounting for Income Taxes

We did not maintain a sufficient complement of resources with adequate experience and expertise in accounting for income taxes, as a result of which our controls did not operate at a level of precision to identify errors in the calculation of tax balances resulting from dispositions and U.S. taxes on foreign earnings. The material weakness resulted in the previous restatements to our consolidated financial statements for the year ended December 31, 2014 and our interim financial information for the three and nine months ended September 30, 2014. This material weakness could result in a material misstatement of the consolidated financial statements that would not be prevented or detected.

Material Weaknesses Related to Revenue Recognition

We did not maintain a sufficient complement of resources at our subsidiaries with appropriate knowledge, experience and training to ensure proper application of US GAAP in determining revenue recognition.

We also did not maintain effective controls over information and communications as it relates to revenue recognition at our subsidiaries. Specifically, we did not implement and reinforce an adequate process for internally communicating nonstandard terms and conditions between our subsidiaries’ commercial operations and finance groups and between our subsidiaries’ finance groups and our corporate accounting group. These material weaknesses contributed to the following material weaknesses.

We did not design effective controls over the review of terms of purchase orders and customer contracts, including amendments to contracts, to ensure proper application of US GAAP in determining revenue recognition.

We did not design effective controls to ensure that revenue would not be recognized until title and risk of loss had passed to our customers.

These material weaknesses resulted in a revision to our financial statements for the years ended December 31, 2013 and 2014 and each of the interim periods in 2014 and 2015. Although the adjustments resulting in the revision to our financial statements were not material, we concluded that these material weaknesses could result in a material misstatement of the consolidated financial statements that would not be prevented or detected.

Plan for Remediation of Material Weaknesses in Internal Control Over Financial Reporting

With the oversight of senior management, including our Chief Executive Officer, our Chief Financial Officer and our Chief Accounting Officer, and the audit committee of our board of directors, we have implemented, and will continue to identify and implement, steps to remediate the material weaknesses described above. The specific actions taken and planned additional actions are described below.

Material Weakness Related to Accounting for Income Taxes

 

    supplementing our accounting and tax professionals with additional personnel with the appropriate experience, certification, education, training and expertise in accounting for the income tax effects of dispositions and other complex transactions. Between May 1, 2015 and June 30, 2016, we hired a Corporate Controller and Chief Accounting Officer, Vice President, Global Tax, a Senior Director, International Tax, a Director, Global Tax Accounting, a Senior Manager, Global Tax Accounting, and a Senior Manager, Domestic Tax, all of whom have experience working on tax provisions of multinational companies;

 

    enhancing our income tax controls to include specific activities to assess the accounting for deductible outside basis differences that could reverse as a result of transactions to dispose of components of the company. Between May 1, 2015 and June 30, 2016, Company tax department personnel have attended internal and external trainings related to income tax accounting; and

 

    enhancing our controls over the income tax provision process to include specific controls over the determination of U.S. taxes on foreign earnings.

Material Weakness Related to Revenue Recognition

 

    hiring additional Finance personnel to support our commercial subsidiaries who have experience working in global finance organizations and have expertise in revenue recognition and US GAAP. Specifically, in 2015 and 2016, we hired new finance directors in Latin America and Africa and plan to hire additional resources at some of our foreign subsidiaries;

 

56


Table of Contents
    reorganizing Finance and commercial operations to facilitate global communication to enhance compliance with the corporate revenue recognition policy and US GAAP;

 

    enhancing the formal contract and purchase order review process at our commercial subsidiaries to ensure appropriate application of US GAAP, including approvals at appropriate levels;

 

    creating and implementing formal global processes that require revenue recognition subject matter experts to review and approve any nonstandard arrangements, including significant transactions, significant promotional programs, sales incentives or other deviations from standard order fulfillment processes;

 

    formalizing periodic revenue recognition training for all finance, order fulfillment and customer-facing employees;

 

    expanding the scope of internal audit testing of controls over the order-to-cash cycles at subsidiaries as well as, implementing more precise entity level controls related to revenue transactions to ensure strict adherence to Company policy and procedures

These ongoing actions are subject to ongoing review by our senior management, as well as oversight by the audit committee of our board of directors. Although we plan to complete this remediation process as quickly as possible, we cannot, at this time, estimate when such remediation may occur, and our initiatives may not prove successful in remediating these material weaknesses. Management may determine to enhance other existing controls and/or implement additional controls as the implementation progresses. It will take time to determine whether the additional controls we are implementing will be sufficient to accomplish their intended purpose; accordingly, these material weaknesses may continue for a period of time. While the audit committee of our board of directors and senior management are closely monitoring this implementation, until the remediation efforts discussed in this section, including any additional remediation efforts that our senior management identifies as necessary, are completed, tested and determined effective, we will not be able to conclude that these material weaknesses have been remediated.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

Abbott Laboratories

On August 25, 2016, Alere Inc. filed suit against Abbott Laboratories in the Delaware Chancery Court, and filed an accompanying motion to expedite the proceedings. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We have asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement. On August 30, 2016, Abbott filed its response in opposition to the motion to expedite the proceedings in this matter. On September 2, 2016, the Delaware Chancery Court granted our motion to expedite the proceedings.

U.S. Securities and Exchange Commission Subpoenas

On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users in Africa, as well as revenue recognition relating to sales of products and services to end-users in Africa. We have also received, from time to time, requests in connection with the investigation to voluntarily produce additional information to the SEC, including information pertaining to certain other countries in Asia and Latin America.

We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it.

Department of Justice Grand Jury Subpoena

On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act.

We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it.

Securities Class Actions

On April 21, 2016, a class action lawsuit captioned Godinez v. Alere Inc., was filed against us in the United States District Court for the District of Massachusetts. On May 4, 2016, a second class action lawsuit captioned Breton v. Alere Inc., was filed against us in

 

57


Table of Contents

the United States District Court for the District of Massachusetts. Both of these class actions purport to assert claims against us and certain current and former officers for alleged violations of Section 10(b) and Section 20(a) of the Exchange Act and Rule 10b-5 under the Exchange Act. Each plaintiff seeks to represent a proposed class of all persons who purchased or otherwise acquired our common stock during the period May 9, 2013 through April 20, 2016. Each complaint seeks damages allegedly caused by alleged materially misleading statements and/or material omissions by us and the officers regarding our business, prospects and operations, each plaintiff claims, which allegedly operated to inflate artificially the price paid for our common stock during the class period. Each complaint seeks unspecified compensatory damages, attorneys’ fees and costs. On July 11, 2016, the court entered an order consolidating the two actions and appointing lead plaintiffs and lead counsel, and on July 19, 2016, the court ordered a schedule for the filing of a consolidated amended complaint and for the motion to dismiss briefing.

We are unable at this time to determine the outcome of this class action lawsuit or our potential liability, if any.

Matters Relating to our San Diego Facility

On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out of the October 2012 warning letter could not occur until after a future inspection.

In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the government and are responding to the investigation, which is ongoing. We have been engaged in discussions with the government about this matter, including a resolution of potential related False Claims Act and common law liability exposure for the products under review. As a result of these discussions, management has accrued $10.2 million for this matter in the three months ended June 30, 2016. We would need to obtain certain approvals before we could agree to any proposed resolution. There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to or finalized. We may be required to engage in litigation of this matter, which may be time consuming and costly. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution, the ultimate amount of potential loss may materially exceed the accrual we have established.

We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them.

INRatio Class Actions

On May 26, 2016, a class action lawsuit captioned Dina Andren and Sidney Bludman v. Alere Inc., et al., was filed against us in the United States District Court for the Southern District of California. In addition, on July 22, 2016, a class action lawsuit captioned J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., was filed against us in the United States District Court for the District of Massachusetts. These class actions purport to assert claims against us under several legal theories, including fraud, breach of warranty, unjust enrichment and violation of applicable unfair competition/business practice statutes in connection with the manufacturing, marketing and sale of our INRatio products. The plaintiffs in the Dina Andren and Sidney Bludman class action seek to represent a proposed class of all persons who purchased, rented or otherwise paid for the INRatio system during the period January 1, 2009 to May 26, 2016 in the United States, or alternatively, California, Maryland and/or New York. The plaintiffs in the J.E, J.D., and all others similarly situated class action seek to represent a proposed class of all persons who purchased, rented or otherwise paid for the INRatio system during the period April 1, 2008 to present. Both class action complaints seek restitution and damages allegedly resulting from inaccurate PT/INR readings and from the purchase of devices that claimants say they would not have purchased had they known of the alleged propensity of these devices to yield inaccurate PT/INR results. Among other things, plaintiffs in these class action lawsuits seek a refund of money spent on INRatio products. Each complaint also seeks unspecified compensatory damages, injunctive relief, attorneys’ fees and costs. The Andren action also appears to seek damages for personal injury.

We are unable, at this time, to predict the outcome of these class action lawsuits.

Claims in the Ordinary Course and Other Matters

We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. In addition, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. We are cooperating with these investigations and are providing documents in response to both subpoenas. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, the most recent of which was received in July 2016, from the United States Attorney for the Middle District of Tennessee in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The CIDs

 

58


Table of Contents

request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence relating to the same, dating back to January 2010. We are cooperating with the investigation and are providing documents responsive to the CIDs. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on Alere or its subsidiaries.

We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio System, including documents relating to prior interactions with the FDA and others regarding the system.

Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by private third-party payers, including health insurers, Zone Program Integrity Contractors, or ZPICs, and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support or claims relating to the medical necessity of certain testing and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error.

Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above).

Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could adversely impact our business, results of operations, financial condition, and cash flows.

 

ITEM 1A. RISK FACTORS

Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which was filed with the SEC on August 8, 2016. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

 

ITEM 3. DEFAULT UPON SENIOR SECURITIES

As previously disclosed, as of March 31, 2016, we were in default under the Credit Agreement and the respective indentures

governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible

senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the

fiscal year ended December 31, 2015. We subsequently entered into an amendment and obtained waivers with respect to such debt

instruments (other than with respect to our 3% convertible senior subordinated notes) with the requisite holders of such debt with

regard to such defaults and certain other defaults thereunder (including our subsequent failure to timely furnish to the holders of such

debt our quarterly financial statements for the three months ended March 31, 2016). For more information regarding this default and

these amendments and waivers, see Note 12 to the consolidated financial statements “Long-term Debt” included elsewhere in this

Quarterly Report on Form 10-Q.

 

ITEM 6. EXHIBITS

 

Exhibit
No.

  

Description

10.1    First Amendment, dated as of April 22, 2016, among the Company, certain subsidiaries of the Company, the several lenders from time to time party thereto, Goldman Sachs Bank USA as B term loan administrative agent, Healthcare Financial Solutions, LLC, as pro rata administrative agent, to the secured Credit Agreement, dated as of June 18, 2015, among the Company, the several lenders from time to time party thereto, the Administrative Agents and certain other agents and arrangers (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, event date April 22, 2016, as filed with the SEC on April 28, 2016).

 

59


Table of Contents

Exhibit
No.

  

Description

*31.1    Certification by Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*31.2    Certification by Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
*32.1    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*101    Interactive Data Files regarding (a) our Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2016 and 2015, (b) our Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2016 and 2015, (c) our Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015, (d) our Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015 and (e) the Notes to such Consolidated Financial Statements.

 

* Filed herewith
Management contract or compensatory plan or arrangement, of amendment thereto

 

60


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      ALERE INC.
Date: September 2, 2016     By:  

/s/ Jonathan Wygant

      Jonathan Wygant
      Chief Accounting Officer and Corporate Controller and an authorized officer

 

61